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- 2-AAF      2-acetylaminofluorene 
- AFB1      aflatoxin B1 
- AFP      α-fetoprotein 
- APC      adenomatosis polyposis coli 
- APP      amyloid β precursor protein 
- BMI      body mass index 
- BrdU      5'-bromo-deoxyuridine 
- CDKN2A     cyclin-dependent kinase inhibitor 2A 
- CSCs      cancer stem cells 
- CTNNB1     β-catenin 
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- DIO      deiodinase 
- DNMTs     DNA methyltransferase enzymes 
- EpCAM     epithelial cell adhesion molecule 
- ERK      extracellular signal-regulated kinase 
- ERα      estrogen receptor α 
- FNH      focal nodular hyperplasia 
- G6PC      glucose-6-phosphatase 
- GSK-3β     glycogen synthase kinase-3β 
- GST-P      placental glutathione-S-transferase 
- HBV      hepatitis B virus 
- HCC      hepatocellular carcinoma 
- HCV      hepatitis C virus 
- HIF-1α     hypoxia inducible factor-1α 
- HIV      human immune-deficiency virus 
- ICC      intrahepatic cholangiocarcinoma 
- IGF-2      insulin-like growth factor-2  
- IGF-2R     insulin-like growth factor-2 receptor 
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Introduction 
 
HEPATOCELLULAR CARCINOMA 
 
Epidemiology 
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and a 
major health problem worldwide. Incidence is increasing and HCC has risen to became the 
5th commonest malignancy worldwide and the third leading cause of cancer-related death 
[Parkin DM, 2001] . Globally, there are approximately 750˙000 new cases of liver cancer 
per year. Population-based control studies showed that the incidence rate continues to 
approximate the death rate, indicating that most of the patients who develop HCC die for 
it [Jemal A et al, 2011] . HCC burden is not distributed evenly throughout the world and 
important differences have been noted between countries. Sub-Saharan Africa and Eastern 
Asia are considered to have a very high incidence of HCC (over 20 cases / 100˙000 
population) . Areas with moderate risk (10-20 cases / 100˙000 population) include Italy, 
Spain, France, United Kingdom and Latin American countries, and a relative low incidence 
(5-10 cases / 100˙000 population) is found in the United States, Canada, and in Scandinavia 
[Parkin DM, 2002; Montalto G et al, 2002; Ferlay G et al,1998; Bosh FX et al, 2004] . Although 
encouraging trends in HCC incidence have been observed in some high-rate areas, in 
contrast, its incidence is rising in some low-moderate risk areas [McGlynn KA et al, 2001] . 
The main reasons for the observed increase in HCC incidence, are mainly related to the 
increased occurrence of the hepatitis C (HCV) virus infections and to the increase of 
immigrants from Asia and Africa to North America and Western Europe countries [Di 
Bisceglie AM, 2002; El-Serag HB and Mason AC, 1999; Taylor-Robinson SD et al, 1999; Khan SA 
et al, 2002] . In addition to geographical distribution, the global incidence of HCC is also 
strongly correlated to ethnicity, gender and age. USA are a good example of how the HCC 
incidence also vary greatly among different populations living in the same region; where, 
independently of age and sex, HCC rates are two times higher in Asian than in African 
Americans, whose rates are two time higher than those in whites [El-Serag HB and Rudolph 
KL, 2007] . In almost all populations, males have higher liver cancer rates than females, 
with male:female ratios usually averaging between 2:1 and 4:1. Reasons for higher rates of 
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liver cancer in males may relate to sex-specific differences in exposure to risk factors and it 
is reasonable to think that androgens have an important role in HCC progression. Indeed, 
experiments show a 2- to 8-fold increase in HCC development in male mice [Rudolph KL et 
al, 2000] . Moreover, studies conducted in Taiwan reported a positive association between 
increased circulating testosterone levels and HCC in HBV-infected men [YU MW and Chen 
CJ, 1993; Yu MW et al, 2001] . The global age distribution of HCC varies by region, 
incidence rate, sex and etiology [Parkin DM, 2002] . The incidence of HCC increases with 
age, reaching its highest prevalence among those aged over 65 years and, in almost all areas, 
female reach the peak 5 years later than males [El-Serag HB and Rudolph KL, 2007; El-Serag 
HB, 2007; Parikh S and Hyman D, 2007] . A shift in incidence towards younger ages has 
been noted in the last two decades [Bosch FX et al, 2004] . 
 
Risk factors 
Usually HCC occurs within an established background of chronic liver disease and rarely it 
develops in a healty liver. Cirrhosis is the most important risk factor, with ~ 70-90% of all 
detected HCC cases arising in a cirrhotic liver [Parkin DM et al, 2001] . Other important 
risk factors for HCC development include viral infections (hepatitis B and hepatitis C 
virus), toxic exposures (aflatoxins, pesticides, alcohol intake, tobacco), metabolic disorders 
(non-alcoholic fatty liver disease, diabetes, obesity) and hormonal factors (oral 
contraceptives). Less common causes include hereditary hemochromatosis, α1-antitrypsin 
deficiency, autoimmune hepatitis, and some porphyrias.  
 
Viral factors 
Hepatitis B virus (HBV) 
The WHO has reported HBV to be second only to tobacco smoke as a known human 
carcinogen since about 300 million people have the chronic infection worldwide [WHO, 
2002; El-Serag HB and Rudolph KL, 2007] . HBV is the leading cause of HCC worldwide, 
particularly in Asia and Africa, where HBV is endemic. In these areas, it is usually 
transmitted from mother to newborn (vertical transmission) and 70-90% of HBV-
associated HCC develops in the setting of liver cirrhosis; but even in the absence of 
cirrhosis the infection is an important risk factor [El-Serag HB and Rudolph KL, 2007] . This 
pattern is different in areas with low HCC incidence rates where HBV is acquired in 
adulthood through sexual and parenteral routes (horizontal transmission), with more than 
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90% of acute infections resolving spontaneously [El-Serag HB and Rudolph KL, 2007] . The 
mechanisms of HCC development associated to HBV infection have been extensively 
studied, and both HBV and host hepatocytes may contribute to the final pathogenic 
outcomes, either individually or synergistically [Liu CJ and Kao JH, 2007] . From a global 
perspective, the burden of chronic HBV infection is expected to decline because of the 
increasing utilization of HBV immunization, that actually is the most effective measure for 
the HBV infection prevention [Kane MA, 2003] . 
 
Hepatitis C virus (HCV) 
HCV is the most important risk factor for HCC in Western European and North 
American countries [Montalto G et al, 2002]. Up to 80% of HCV-infected individuals fail to 
eliminate the virus acutely and progress to chronic HCV infection [Suruki RY et al, 2006; 
Tsai SL et al, 1997; Sarih M et al, 2000; Cucchiarini M et al, 2000; Gruner NH et al, 2000] . The 
rate of fibrotic progression following HCV infection is markedly variable, since the natural 
history of the disease typically extends over several decades. Usually, HCC develops after 
10-20 years of HCV infection and the increased risk is largely restricted to patients with 
cirrhosis or advanced fibrosis [El-Serag HB and Mason AC, 2000] . In contrast to HBV, in 
HCV-infected patients, host and environment factors appear to be more important than 
viral factors in determining progression to cirrhosis. These factors include older age at the 
time of infection, male sex, heavy alcohol intake (>50gr/day), diabetes , obesity and co-
infection with human immune-deficiency virus (HIV) or HBV [Cramp ME, 1999] . Follow-
up studies have shown that patients with combined HBV and HCV infection have a higher 
risk of developing HCC than those with HBV or HCV alone [Montalto G et al, 2002, 
Michielsen PP et al, 2005; Sato S et al, 1994] . The cumulative risk of developing HCC was 
23%, 10% and 21%, respectively, after 5 years and 45%, 16% and 28%, respectively, after 
10 years [Montalto G et al, 2002; Chiaramonte et al, 1999] . 
 
Environmental factors 
Aflatoxin B1 (AFB1) 
Aflatoxin B1 is a mycotoxin produced by the Aspergillus flavus and Aspergillus parasiticus fungi. 
In Asia and sub-Saharan Africa, climatic factors and storage techniques favor the fungus to 
be a common contaminant of foods, such as grain, corn, peanuts and legumes stored in 
warm and damp conditions. Animal experiments showed that AFB1 is a powerful 
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hepatocarcinogen, leading the International Agency for Research on Cancer to classify it as 
carcinogenic compound [IARC, 1987] . AFB1 is metabolized to an active intermediate, 
AFB1-exo-8,9-epoxide, which can bind to DNA and cause damage, including a 
characteristic mutation in the p53 tumor-suppressor gene (mutation of codon 249, 249ser) 
[Garner RC et al, 1972] . This mutation has been observed in 30-60% of HCCs in aflatoxin-
endemic areas [Bressac B et al, 1991; Turner PC et al, 2002]. Furthermore, short-term 
prospective studies in Shanghai, have shown an interaction between AFB1 exposure and 
chronic HBV infection. These studies have demonstrated that the urinary excretion of 
aflatoxin metabolites was associated with a 4-fold increase in HCC risk, whereas HBV 
infection increased the risk 7-fold. However, HBV carriers who excreted AFB1 metabolites 
had a dramatic 60-fold increased risk of HCC [Qian GS et al, 1994] . Indeed, it has been 
observed that areas with a high prevalence of HCC and high aflatoxin intake also 
correspond to areas with endemic HBV infection [Montalto G et al, 2002; Groopman JD et al, 
1996] . 
 
Pesticides 
Pesticides exposure is one of the environmental factors hypothesized to increase the risk of 
HCC. Pesticides are believed to exert their carcinogenic potential through one or several 
mechanisms, such as spontaneous initiation of genetic changes, cytotoxicity with persistent 
cell proliferation, oxidative stress, inhibition of apoptosis and suppression of intracellular 
communication [Rakitsky VN et al, 2000; Ezzat S, et al, 2005] . A case-control study of 
HCC in HBV and/or HCV infected patients from Egypt suggested that pesticides had an 
additive effect on the risk of HCC in rural males, amongst whom the use of carbamate and 
organophosphate compounds is commonplace [Ezzat S et al, 2005] .  
 
Alcohol 
Heavy alcohol intake is a well-established HCC risk factor. Depending on the geographical 
areas analyzed, it can act as a primary cause for the HCC onset or as a cofactor. In USA 
and in several countries of Western Europe, where there is a high rate of alcohol 
abuse/addiction, it acts as a primary cause of tumor development. It has been 
demonstrated that the ingestion of more than 80gr/day of alcohol for more than 10 years 
increases the risk of developing cancer about 5 times. Instead, alcohol acts as cofactor in 
developing countries, where its consumption is accompanied by other risk factors, such as 
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HBV and HCV virus or diabetes. There is also evidence that in the presence of 
concomitant HCV infection, there is an additional 2-fold increase in HCC risk. Although 
heavy intake is strongly associated with the development of cirrhosis, there is little evidence 
of a direct carcinogenic effect of alcohol otherwise. The mechanism by which alcohol 
causes HCC is still not well known but it is hypothesized that oxidative stress, altered 
retinoic acid metabolism, DNA methylation, genetic susceptibility and decreased immune 
surveillance may play an important role in tumor development [Morgan TR et al, 2004] . 
 
Tobacco smoke 
Several studies conducted in both low- and high-rate HCC areas examined the relationships 
between cigarette smoke and HCC but of more than 40 studies that examined the 
association between 1983 and 2002, the number of studies which reported positive 
associations was almost equal to the number with no associations [Schottenfeld D et al., 
2006]. Taken together, the available evidence suggest that tobacco alone is not an 
important risk factor for HCC but the risk is highly increased in the presence of other risk 
factors, such as HBV, HCV, heavy alcohol intake and other exposure [El-Serag HB and 
Rudolph KL, 2007; Evans AA et al, 2002].  
 
Metabolic disorders 
Several epidemiological studies conducted mainly in the United States, failed to identify a 
significant association between well-established risk factors and HCC development for 
more than 50% of cases. These cases seem to be not attributable to the most common risk 
factors (chronic infection by HBV, HCV, alcohol consumption). Among these patients, a 
large rate includes patients with metabolic disorders [Davila JA et al, 2005] , such as 
nonalcoholic fatty liver disease, obesity and diabetes . 
 
Nonalcoholic fatty liver disease (NAFLD) 
NAFLD is the most common liver disorder in Western countries. In the United States 
more than 30% of people are affected and 90% of them are obese (body mass index ≥ 
40kg/m2) [Browning JD et al, 2004 ; Lazo M, Clark JM, 2008] . It occurs in the absence of 
alcohol intake, although liver histology appears consistent with alcoholic hepatitis. The 
most serious form of NAFLD is represented by nonalcoholic steatohepatitis (NASH) 
[Falck-Ytter Y et al, 2001; Angulo P. et al; 1999] , that represents the hepatic manifestation of 
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several metabolic disorders such as obesity and diabetes mellitus type 2 [Abdelmalek MF, 
Diehl AM., 2007] ; indeed NASH manifests nearly universally among diabetic patients who 
are morbidly obese [Adams LA et al, 2005] . Moreover, NASH in association with other 
components of the metabolic syndrome is thought to increase the risk of developing 
chronic liver disease, cirrhosis and HCC [Bugianesi E. et al, 2007] . A recent study has shown 
that NAFLD is a principal risk factor in the development of HCC, irrespective of age 
[Sanyal AJ et al, 2009] . This association is alarming, due to the globally high prevalence of 
these conditions and may contribute to the rising incidence of HCC observed in many 
industrialized countries. 
 
Obesity 
Several large-scale epidemiological studies have associated the increasingly prevalent 
overweight and obesity with a higher risk of HCC [Calle EE et al, 2003 ; Bianchini F et al, 
2002] . In a cohort of 900˙000 American adults, the risk of dying from liver cancer was 4.5 
times higher in men with a body mass index (BMI) ≥35kg/m2 or above compared to the 
reference group with a normal BMI (18.5 to 24.9kg/m2) [Calle EE et al, 2003] . A recent 
meta-analysis concluded that the summary relative risk of liver cancer was 117% for 
overweight subjects and 189% for obese individuals [Larsson SC and Wolk A, 2007] .  
 
Diabetes 
Type 2 diabetes is an increasingly common metabolic disorder strongly linked to obesity 
and characterized by hyperglycemia, insulin resistance, and hyperinsulinemia. It has been 
associated with increased risk of several cancers. Substantial evidence indicates that 
diabetes promotes development and progression of HCC [Giovannucci E et al, 2010 ; El-
Serag HB et al, 2006] . A population-based study that evaluated 14% of the United States 
population found that diabetes conferred a three-fold risk of HCC [Davila JA et al, 2005] . 
The association between diabetes and HCC has been further demonstrated by studies 
focused on populations from different geographical locations indicating that in most 
individuals diabetes may exist for a long time before the diagnosis of HCC and that there 
are synergistic interactions between diabetes and other HCC risk factors [Baffy et al, 2012; 
Hassan MM et al, 2002] . 
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Ormonal factors 
There is experimental rationale for a possible role of oral contraceptives (OCs) in the 
development of liver neoplasia. Nuclear estrogen receptors are expressed in hepatocytes 
and are increased in HCC, suggesting a hormonal responsiveness of hepatic neoplastic 
tissue [El-Serag HB and Rudolph KL, 2007] . Estrogen and progesterone components of OCs 
have been shown to induce and promote liver tumors in animals [Yu MC and Yuan JM, 
2004] , probably because estrogens increase proliferation rates, thereby increasing rates of 
spontaneous mutations [De BV et al, 1996] . Several human studies have reported an 
increased risk of developing benign liver tumors, such as hepatic cell adenoma and focal 
nodular hyperplasia in women using OCs [Korula J et al , 1991] . OC usage also has been 
linked, although unfrequently, to malignant liver tumors such as HCC, mixed 
hepatocellular and ductal carcinoma, cholangiocarcinoma and hepatoblastoma [Rosenberg L , 
1991] .  
 
Natural history of HCC  
Hepatocellular carcinoma development is a multistep process and it nearly always develops 
in the setting of chronic hepatitis or cirrhosis. Retrospective studies focused on HCV 
patients suggest that HCC manifestation takes about 10 years after diagnosis of cirrhosis 
and about 30 years after exposure to the virus [Kiyosawa K. Et al, 1990] . Conversely, HBV 
related carcinogenesis is less predictable because HCC development may precede the 
occurrence of cirrhosis, especially in geographic areas in which the HBV infection is 
endemic [McMahon BJ, 2005] . 
The natural history of HCC is fairly long and can be divided into three distinct phases:  
1) molecular ; 2) preclinical ; 3) clinical or symptomatic [Trevisani F et al, 2008] . 
1) Molecular phase: The molecular phase includes the sequential genomic alterations leading to 
cell transformation. It has been postulated that the transformed cell can be either a 
hepatocyte/biliary epithelial or a liver stem cell [D’ Errico A et al, 1996] . Mechanisms of 
cellular transformation are different depending on the cell type. Genetic alterations 
involving differentiated cells (hepatocytes and cholangiocytes) are thought to confer a 
growth advantage by promoting proliferation and inhibiting apoptosis, whereas those 
involving stem cells interfere with the differentiation process [Trevisani F et al, 2008] . 
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2) Preclinical phase: is divided in two phases; an initial period, in which the tumor is still too 
small to be detected by imaging techniques, and a second period, during which the tumor is 
detectable but still asymptomatic. 
3) Clinical or symptomatic phase: is characterized by the occurrence of symptoms caused by the 
tumor burden. In patients with chronic liver disease, HCC usually becomes symptomatic 
when it reaches a size of 4.5–8cm [Yuen MF et al, 2000 ; Trevisani F et al, 2002] . 
 
The complex etiology of HCC affects the possible treatment options offered to patients. 
Treatments for HCC have been conventionally divided into curative and palliative. Curative 
treatments, such as resection, liver transplantation, and percutaneous ablation, are the most 
effective treatments for patients with early-stage disease since they can induce a complete 
response in a high proportion of patients and are expected to improve survival. Palliative 
treatments are applied to patients with advanced tumor stages, therefore with poor hepatic 
and extra-hepatic functions. Palliative treatments include chemotherapy agents and 
symptomatic drugs, the latter especially applied to end-stage patients [Josep M Llovet et al, 
2003] . 
Two decades ago, HCC prognosis was dismal because diagnosing at advanced stages 
precluded the optimum use of radical treatments and most patients died within 1 year, 
irrespective of treatment [Okuda K et al, 1985] . In developed countries this scenario has 
completely changed, since 30-40% of patients are now being diagnosed at initial stages 
when curative treatments can be optimally applied [Bruix J and Llovet JM, 2002] . Indeed, 
the short-term prognosis of patients with HCC has improved, but long term prognosis 
remains unsatisfactory and survival at 5-10 years after curative treatments remains dismal 
[Masuzaki R et al, 2008; Shiina S et al, 2012] . One of the most important reasons that 
contribute to the poor prognosis is that patients with HCC usually show important liver 
dysfunctions, generally as a result of cirrhosis, and consequently are ineligible for surgical 
and non-surgical treatments. Given the established links between liver cirrhosis and 
development of HCC, there is a strong rationale for surveillance of patients with cirrhosis, 
and guidelines support observation of this group, regardless of etiology [Arun J. Sanyal, 
2010] . Prevention of HCC is also an important goal, and opportunities exist to advance 
the development of preventive measures. The success of preventive intervention was first 
demonstrated by the vaccination program against HBV which was implemented in the 
1980s and successfully reduced both the number of HBV carriers and the incidence of 
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HCC in children. Moreover, studies performed in patients with HCV, with and without 
cirrhosis, have shown that treatment with interferon therapy is associated with a lower risk 
for developing HCC [Chang MH, 1997; Ni YH et al, 2001; Ni YH et al, 2007; Chang et al, 
2009] . The serum marker α-fetoprotein (AFP) and ultrasounds represent the most relevant 
diagnostic tests for HCC, however levels of sensitivity and specificity of these screenings 
are very limited when used alone; combining ultrasonography and AFP appears to improve 
detection rates [Ryder SD, 2003] .  
 
Molecular mechanisms 
Advances in molecular profiling studies using DNA microarray-based gene-expression 
experiments have provided increased awareness about the regulatory networks altered in 
human HCC and have also provided useful gene expression-based signatures that can 
distinguish tumor subtypes, assist clinical staging and predict patient outcomes. As 
mentioned above, more than 90% of HCC cases develop in the setting of chronic hepatitis 
or cirrhosis suggesting that chronic inflammation plays a key role in altering the liver 
microenvironment, increasing the risk of carcinogenesis [Grisham JV, 2001; Bosh FX et al, 
1999; Buendia MA, 2000] . Therefore, there is a strong need to elucidate the molecular 
mechanisms that predispose to tumor development, especially those involved in the 
inflammatory pre-neoplastic phase. To explain hepatic carcinogenesis, two models are 
currently proposed: the first one is the clonal evolution model that implies a multi-step 
process of tumor development from precancerous lesions to metastatic carcinoma ; the 
second model, recently proposed, is the cancer stem cells model [Kumar M et al, 2011] . 
 
The clonal evolution model of hepatocarcinogenesis 
The longstanding clonal evolution model for HCC development is a multistep event, which 
may take as long as 30 years to unfold. The various etiological factors, particularly 
inflammation and viral hepatitis, seem to contribute significantly to approximately 90% of 
HCC cases by creating phenotypically altered hepatocytes. The main causes of HCC (viral 
hepatitis, alcoholic hepatitis and non-alcoholic steatohepatitis) typically give rise to hepatic 
alterations culminating in a chronic inflammation of the liver [El-Serag HB, Rudolph KL, 
2007] . In this conditions many hepatocytes die, inflammatory cells invade the liver and 
connective tissue is deposited [Thorgeirsson SS & Grisham JW, 2002] . For example, in 
chronic viral hepatitis, the host immune responses to HBV or HCV are often unable to 
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completely clear the infection, resulting in chronic stimulation of an antigen-specific 
immune response [Budhu A and Wang XW, 2006] . Virus-infected hepatocytes are killed by 
host immune cells and by the intrinsic cytopathic effects of the hepatitis viruses, triggering 
the production of various cytokines and growth factors and subsequently inducing 
compensatory hepatocyte regeneration. This persistent cycle of necroinflammation and 
hepatocyte regeneration is thought to increase the risk of genetic mutation in hepatocytes, 
and furthermore, to promote survival and expansion of initiated cells [Levrero M, 2006; 
Maeda S, 2010; He G and Karin M, 2011] . Additionally, reactive oxygen species (ROS) and 
nitrogen oxygen species (NOS), generated by both initiated cells and inflammatory cells, 
could accelerate hepatocarcinogenesis through several mechanisms, such as the induction 
of oxidative DNA damage, DNA methylation, and hepatocyte injury [He G and Karin M, 
2011] . The result of these conditions is the production of phenotypically altered 
hepatocytes that are considered monoclonal in origin [Yeh SH et al, 2001; Aihara T et al, 
1994] . These aberrant hepatocytes, through a multistep process, initially give rise to 
development of preneoplastic foci, which with further accumulation of mutational events 
and aberrant growth, can transform into primary HCC and finally metastatic HCC 
[Sakamoto M et al, 1991] . Progression of hepatocarcinogenesis is associated with multiple 
molecular mechanisms which together lead to the loss of tumor suppressor genes and to 
the gain of oncogenes as a consequence of genetic and epigenetic alterations that represent 
the basis for the alteration of important signaling pathways [Kumar M et al, 2011] . 
 
Genomic alterations 
HCCs are deeply heterogeneous and characterized by a multitude of chromosomal 
alterations that gradually accumulate during the carcinogenic process [Wilkens L et al, 2002]. 
Previous genome-wide gene expression studies have revealed altered gene expression 
patterns that correlate with clinical outcome [Woo HG et al, 2011] . Moreover, comparative 
genomic studies and SNP-arrays, through a comparison between HCC samples and non 
tumoral tissue, have been necessary to highlight a wide mixture of genomic aberrations that 
can be used as fingerprints to clarify different tumor features and to distinguish between 
different tumor subtypes [Wilkens L et al, 2000; Chen YJ et al, 2000] . Several studies 
reported that human HCCs are frequently characterized by chromosomal amplifications at 
arms 1q, 6p, 8q and 17q [Thorgeirsson SS and Grisham JW 2002; Homayounfar K et al, 2009] 
that may result in activation of oncogenes, such as the activating mutations of the β-catenin 
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(CTNNB1) gene [Wong CM et al, 2001; Miyoshi Y et al, 1998] , whereas chromosomal 
deletions and loss of heterozygosity (LOH) were found respectively in the chromosomal 
arms 1p, 1q, 4q, 5q, 6q, 8p, 9p, 13q, 16p,16q and 17p and 1p, 4q, 6q, 8 p, 9p, 13q, 16p, 16q, 
17p [Thorgeirsson SS and Grisham JW 2002; Homayounfar K et al, 2009; Laurent-Puig P et al, 
2001; Nagai H et al, 1997] . The loss of these regions has been associated with loss of tumor 
suppressor genes such as  TP53 (p53), retinoblastoma RB1 (pRb) [Edamoto Y et al, 2003; 
Murakami Y et al, 1991] , CDKN2A (p16INK4A) [Laurent-Puig P et al, 2001; Liew CT et al, 
1999] and insulin-like growth factor-2 receptor (IGF-2R) [De Souza AT et al,1995; Oka Y 
Et al, 2002] . 
 
Cellular signaling pathways involved in hepatocarcinogenesis 
Wnt/β-catenin. The Wnt signaling pathway was originally identified in Drosophila 
melanogaster and is evolutionary conserved in nematodes, insects and vertebrates [Cox RT & 
Peifer M, 1998] . The most critical and studied Wnt pathway is the canonical Wnt pathway, 
which functions by regulating the amount of the transcriptional coactivator β-catenin that 
controls key developmental gene expression programs involved in the control of 
embryonic development and adult homeostasis. In the absence of Wnt signaling, 
cytoplasmic β-catenin complexes with the tumor suppressor adenomatosis polyposis coli 
(APC), with Axin1, and with glycogen synthase kinase-3β (GSK-3β). In this complex, 
GSK-3β phosphorilates β-catenin, targeting it for ubiquitination and subsequent 
degradation. When Wnt signaling receptors are engaged, conformational changes in the 
Axin complex cause the release of β-catenin, which then localizes to the nucleus and 
activates transcription of target genes such us Myc, Cyclin D1 and COX2 [Chiba T et al, 
2007; Clevers H 2006; Kikuchi A, 2000] . In HCC, several transcriptomic and proteomic 
studies have indicated an increase in Wnt signaling, possibly as a result of an accumulation 
of Axin1 mutations at sites that bind β-catenin and/or CTNNB1 mutations along sites 
marked for phosphorylation by GSK-3β [Yamashita T et al, 2009; Cavard C et al, 2008].  
p53. TP53 gene encodes the p53 protein which plays a pivotal role in the DNA-damage 
response network, including cell cycle arrest, apoptosis, DNA repair and cellular 
senescence. Therefore, is not surprising that TP53 loss of function mutations or allelic 
deletions in chromosome 17p are commonly associated with human carcinogenesis 
[Hussain SP and Harris CC, 2006] . Aflatoxin B1 is a mutagen for the TP53 gene, causing 
G:C to T:A transvertions at the third base pair in codon 249 (converting arginine to serin), 
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and the rate of TP53 R249S mutation may be accelerated in the presence of viral infection 
[Aguilar F et al, 1993; Kirk GD et al, 2005] . Furthermore, HBV encodes a viral protein, 
HBx, which can specifically bind to p53 and suppress p53-induced apoptosis [Wang XW et 
al, 1994].  
pRB. The tumor suppressor retinoblastoma (pRb1) is a nuclear protein encoded by the RB 
gene, located on chromosome 17 [Dynlacht BD et al, 1994] . pRb is a major cellular barrier 
to cancer development and it controls cell cycle progression at the Restriction Point G1/S 
via repression of the E2F transcription factor family of proteins. In human HCC, the pRB 
signaling pathway is altered in more than 80% of cases. 
Myc. Myc is a potent oncogene, which appears to be constitutively up-regulated in many 
human cancers, representing a phenomenon of ―oncogene addiction‖. Its increased 
expression in HCC is commonly caused by the activation of its locus through chromosome 
amplification [Wilkens L et al, 2004] . One possible mechanism by which Myc contributes 
to hepatocarcinogenesis is through the induction of telomerase, thereby bypassing cellular 
senescence [Wu KJ et al, 1999].  
PI3K/PTEN/Akt. Akt is involved in a number of biological processes, such as cell 
survival, cell growth, apoptosis and differentiation. The activation of the Akt pathway is 
mediated by either an activated tyrosine kinase receptor, or more rarely by the constitutive 
activation of PI3K or the loss of phosphatase and tensin homolog (PTEN), a negative regulator 
of Akt. The loss of PTEN expression via a loss of heterozigosity in chromosome 10q along 
with an activation of Akt has been reported in 40%-60% of HCC cases [Hu TH et al, 2003; 
Blanco-Aparicio C et al, 2007] .  
TGF-β/ IGF-2. TGF- β is an inflammatory cytokine implicated in an array of functions 
such as cell growth, differentiation, migration, apoptosis, adhesion, survival and immunity 
[Derynck R et al, 2001] . IGF-2R, a tumor suppressor gene, promotes the degradation of 
IGF-2 and also the simultaneous activation of transforming growth factor- β (TGF- β) 
signaling, thereby halting cell proliferation and carcinogenesis [Dennis PA and Rifkin DB, 
1991] . Inflammation and subsequent genomic mutations in IGF-2R result in IGF-2 over-
expression and a reduction in the inhibitory effects of TGF-β signaling, a feature 
commonly observed in the development of HCC [Breuhahn K et al, 2004; El-Serag HB and 
Rudolph KL, 2007] .   
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The cancer stem cells (CSCs) model  
This model, recently proposed, may provide a more personalized approach to address 
diagnostic and therapeutic strategies in the clinic. This model hypothesizes that HCC could 
be derived from progenitor cells or de-differentiated transformed cells, thereby explaining 
the heterogeneity in HCC morphology, clinical, behavior, and molecular profiling 
[Yamashita T et al, 2009; Yang XR et al, 2010] . Since the liver is an organ with regenerative 
capability, it has bi-potential progenitor cells that can give rise to hepatocytes or 
cholangiocytes, which could possibly develop into HCC or ICC (intrahepatic 
cholangiocellular carcinoma), respectively [Haruna Y et al, 1996; Wu PC et al, 1999] . The 
cancer stem cell model is not intended to be contradictory to the step-wise model, but 
merely complementary in explaining the origin of a more comprehensive group of HCC 
cases and the arising issues in diagnosing and treatment. For example, mature hepatocytes, 
cholangiocytes or bi-potential progenitor cells that acquire mutations through random 
genetic or epigenetic events can introduce a genetic imbalance in the primary tissue, 
resulting in the de-differentiation of mature cells and the loss of cell cycle control and/or 
the ability to continuously self-renew. Depending on the extent of genetic alterations, the 
tumor cells may remain benign or progress to malignancy. Therefore, events initiated by 
the multistep carcinogenesis model can also result in heterogeneous tumors with stem cell 
capability [Kumar M et al, 2011; Reya T et al, 2001] . ―Liver-specific CSCs‖ have been 
isolated in HCC by several cell surface antigens including CD133, CD90, CD44, OV6, 
CD24, and the epithelial cell adhesion molecule (EpCAM) [Lee TK et al, 2009] . The 
capacity of CSCs for self-renewal and tumorigenesis is thought to involve various cancer-
related signaling pathways that may serve as molecular targets for novel cancer treatment 
strategies. These pathways and potential targets include self-renewal (e.g. Wnt/β-catenin, 
Bmi-1, Notch and Sonic Hedgehog), cell growth (e.g. PTEN and IL-6), survival (e.g. ABC 
multidrug efflux transporters) and differentiation (e.g. hepatocyte nuclear factor–4α) [Lee 
TK et al, 2009; Wang B and Jacob ST, 2011] .  
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EPIGENETICS 
 
The basis of epigenetics 
The term ―epigenetics‖ was originally coined by Conrad Waddington to describe heritable 
changes in a cellular phenotype that were indipendent of alterations in the DNA sequence. 
Despite decades of debate and research, a consensus definition of epigenetics remains both 
contentious and ambiguous [Berger SL et al., 2009] . Today, according to the most accepted 
definition, epigenetics is the study of alterations in gene expression without changes in 
DNA sequence, hence the name epi (Greek: επί- over, above, outer) –genetics [Wu Ct, 
Morris JR, 2001] . Epigenetic mechanisms are involved in regulating many cellular processes 
including embryonic development, chromatin structure, X-chromosome inactivation, 
genomic imprinting, and chromosome stability [Kierszenbaum AL, 2002; Okamoto I et al, 
2004 and Robertson KD, 2005] . These phenomena are mediated by several epigenetic 
modifications, such as DNA methylation at cytosine residues in CpG dinucleotides, histone 
tail methylation, acetylation, phosphorilation, ubiquitynation, sumoylation that result in 
alteration of chromatin structure [Pons D and Jukema JW, 2008] . Generally, CpG 
methylation is associated with heterochromatic gene silencing and with repression of 
transcription in euchromatic regions when occurring at CpG islands of gene promoters, 
while histone modifications can result both in activation or repression of transcription 
based on the specific modification and on the target aminoacid residue in the histone tail 
[Dillon N 2004; Grunstein M, 1997] . DNA and histone modifications influence gene 
expression by making DNA inaccessible (e.g. by adding a methyl group to the DNA) or 
accessible (by removing it) for transcription factors and other proteins involved in gene 
transcription regulation.  
 
DNA methylation 
DNA methylation is one of the most common epigenetic mechanisms of gene silencing. 
The mechanism refers to the binding of a methyl group to the 5th carbon atom of the 
cytosine ring to form a new base, 5-methyl-cytosine (5mC) [Reik W et al., 2001; Goll MC et 
al., 2004] . Patterns of DNA methylation are conserved through DNA replication and are 
inherited by daughter cells; addition of methyl groups takes place immediately after DNA 
replication, and is completed within 1 minute [Reik W et al, 2003; Okuwaki M et al, 2004]. 
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The result of such modification prevents the formation of the transcriptional initiation 
complex, or the elongation of those already initiated [Singal R and Ginder DG, 1999] . The 
CpG dinucleotide is under-represented throughout the genome, but short regions of 0.5-4 
kb in length, known as CpG islands, are enriched in CpG content [Bird A, 2002; Takai D 
& Jones PA, 2002] . Most CpG islands are found at the promoters of 50-60% of all human 
genes and are, generally, unmethylated in normal cells [Jones PA and Baylin SB, 2007] . In 
mammals the methylation mechanism is catalyzed by DNA methyltransferase enzymes 
(DNMTs) that transfer a methyl group to DNA by using S-adenosylmethionine (SAM) as 
the methyl donor. DNA methylation is performed by ―de novo‖ methyltransferases that 
methylate previously unmethylated cytosines, while maintenance of methylation is 
performed by ―maintenance methyltransferases‖, that maintain the methylation pattern 
once it is established [Giannino D et al, 2003; Okano M et al, 1999] . Four isoforms of 
DNMT are known to be involved in DNA methylation: DNMT1, DNMT2, DNMT3A, 
DNMT3B and DNMT3L [Roberts RJ et al, 2003; Kuo HC et al, 2005] . DNMT1 is a 
―maintenance methyltransferase‖ that is responsible for copying of the already established 
methylation pattern by recognizing the hemimethylated sites in DNA helix, and it is 
present always in replication forks of the cells undergoing division [Easwaran HP et al, 2004; 
Pradan S and Esteve PO, 2003] . Inactivation of this enzyme in mice brings about the global 
loss of methylation and abnormal biallelic expression of imprinted genes [Beard LE and 
Jaenisch R, 1993; Howell CY et al, 2001] . In contrast to DNMT1, the biological activity of 
DNMT2 does not demonstrate affinity towards CpG sequences, and knock-out mice for 
this gene do not show recognizable abnormalities [Dong A et al., 2001] . It is assumed that 
this enzyme plays some role in DNA methylation, but it appears not to have any DNA 
methyltransferase activity [Okano M et al, 1998] . Members of DNMT3 subfamily (e.g. 
DNMT3a and DNMT3b) are highly expressed in the developing mouse embryo and 
participate in the processes of de novo methylation that set up DNA methylation patterns 
early in development. Dnmt3L, a protein that by itself has no DNMT activity, colocalizes 
with DNMT3a and DNMT3b and is essential for establishing methylation imprints in the 
female germ line. Genetic analysis of the various DNMTs has established that DNA 
methylation is essential for vertebrate development. Loss of methylation causes apoptosis 
in embryos and fibroblasts, but not in embryonic stem cells or human cancer cells, and 
leads to both widespread de-repression of ectopic gene expression and transcriptional 
activation of transposable elements [Jaenisch R and Bird A, 2003] . DNA methylation can 
 20 
 
influence gene expression in two ways: (1) Directly - the methylation of CpG sequences 
changes the recognition site for a particular transcription factor and (2) indirectly – by 
binding of specific proteins which have affinity for methylated CpG sequences [Meehan RR, 
2003] . These are proteins which bind to methylated CpG groups (methyl-CpG binding 
proteins, MeCPs) via a domain responsible for binding to CpG sequences (methyl-CpG 
binding domain, MBD), and are consequently called MBD1; MBD2, MBD3, MeCP1 and 
MeCP2 [Bird A 2002; Ballestar E 2001] . An altered pattern of DNA methylation  can be 
associated to several diseases, including cancer. Indeed, it has been shown that epigenetic 
silencing as the consequence of aberrant methylation of CpG islands promoter regions, 
results in the loss of function of tumor suppressor genes [Feltus FA et al, 2003; Miyoshi HH 
et al, 2004] . Silencing of the THRβ gene by promoter hypermethylation has been found in 
human cancer including breast, lung, and thyroid carcinoma [Li Z et al, 2002; Iwasaki Y et al, 
2010; Ling Y et al, 2010; Joseph B et al, 2007; Dunwell TL et al, 2009].  
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microRNAs 
 
miRNAs biogenesis and functions 
microRNAs (miRNAs or miRs) are non-coding, single-stranded RNAs of ~22 nucleotides 
(nt) and constitute a novel class of gene expression regulators that are found in both plant 
and animals [Bartel DP, 2004] . Their discovery dates from 1993 and since then thousands 
of miRNAs have been identified [Lee RC, Feinbaum RL and Ambros V 1993] . Many 
miRNAs are evolutionarily conserved from worms to humans, which implies that these 
miRNAs direct essential process both during development and in the adult organism, 
controlling a wide range of biological functions such as cellular proliferation, 
differentiation, apoptosis and stress response. miRNAs negatively regulate the expression 
of protein-coding genes at the post-transcriptional level, by binding to specific, 
complementary sequences located in the 3′-untranslated (3‘-UTR) region of target mRNAs 
in one or two ways depending on the degree of complementarity between themselves and 
the target mRNAs. miRNAs that bind with perfect complementarity to mRNA sequences 
induce the RNA-mediated interference (RNAi) pathway, in which mRNA transcripts are 
cleaved by the miRISC complex. This mechanism is mainly observed in plants but miRNA-
directed mRNA cleavage has also been shown to occur in mammals [Llave C et al, 2002; 
Palatnik J et al, 2003; Tang G et al, 2003; Yekta S et al, 2004]. However, most animal miRNAs 
are thought to bind with imperfect complementary sites within the 3‘-UTRs of their 
mRNA targets and to inhibit the initiation of translation via the miRISC complex , without 
affecting mRNA levels. Recent findings indicate that miRNAs that share only partial 
complementarity with their targets can also induce mRNA degradation, but it is unclear if 
translational inhibition precedes destabilization of target genes [Esquela-Kerscher A and Slack 
FJ, 2006] . Almost 50% of miRNA genes are located in the introns of protein-coding genes 
or long non-coding RNA transcripts, whereas the remainder are independent transcription 
units. Biogenesis of a miRNA begins with the synthesis by Pol II of a long hairpin 
transcript known as pri-miRNA (primary miRNA) which are processed within the nucleus 
by the RNase III Drosha and its cofactor Pasha, in a pre-miRNA (miRNA precursor) of ~ 
70 nt [Lee Y et al, 2002; Zeng Y, Yi R and Cullen BR, 2003; Lee Y et al, 2003] . The nuclear 
export protein Exportin 5 carries the pre-miRNA from the nucleus to the cytoplasm where 
it is subsequently converted to a mature duplex miRNA by another RNAse III enzyme, 
 22 
 
DICER1 to generates a duplex (miRNA:miRNA* duplex) of about 22 nt containing two 
strands, termed miRNA and miRNA*, corresponding to the two sides of the base of the 
stem[Yi R et al., 2003; Lund E et al., 2004]. After binding with the Argonaute protein (Ago), 
the miRNA:miRNA* duplex is incorporated into the miRISC complex (RNA-induced 
silencing complex). One strand of the duplex remains in Ago as mature miRNA (the guide 
strand or miRNA), whereas the other strand (the passenger strand or miRNA*) is degraded 
[Bartel DP, 2004] . Nucleotides 2-7 of the mature miRNA sequence create the ―seed 
region‖ that primarily specifies the target mRNA that the miRNA will bind to [Lewis BP et 
al, 2003; Grimson A, 2007] .  
Computational analysis has shown that a single miRNA can control the expression of 
about one-third of all human mRNAs. Target mRNAs can be diverse in their functions; 
they include transcription factors, secreted factors, receptors and transporters. On the 
other hand, each mRNA can be regulated by different miRNAs [Lim LP et al., 2005; Lewis 
BP et al, 2003] . Several studies have provided evidence that dysregulated miRNA 
expression contributes to initiation and progression of human cancers [Esquela-Kerscher and 
Siack, 2006; Melo SA, 2011] . miRNAs regulate molecular pathways in cancer by targeting 
various oncogenes and tumour suppressors[Zhang B et al, 2007] , and have a role in cancer-
stem-cell biology, angiogenesis, epithelial-mesenchymal transition, metastasis, and drug 
resistance. Loss of miRNA expression can have substantial effects on multiple cellular 
functions and their dysregulation can cause tumorigenesis [Kong Yi W, 2012] . miRNAs can 
be regulated at various levels, including stability, processing, sequence identity and binding 
to target mRNAs. Therefore, these regulatory pathways are susceptible of being altered in 
cancer cells [Kong Yi W, 2012] . Recent studies have reported the involvement of both 
genetic and epigenetic mechanisms in miRNA deregulation that can potentially lead to 
cancer development [Ventura A and Jack T, 2009] . In addition, approximately 50% of all 
annotated human miRNA genes are located at fragile sites or areas of the genome that are 
associated with cancer which are prone to breakage and rearrangement in cancer cells [Calin 
GA et al., 2004] . Since the control of gene expression by miRNAs is strongly dependent on 
their mRNA targets, they can behave as oncogenes and/or tumor suppressor genes, 
depending on the function performed by their targets [Ventura A and Jack T, 2009; Plasterk 
RH, 2006] . Those microRNAs whose expression is increased in tumors may be considered 
as oncogenes. These miRs, called ―oncomirs‖, usually promote tumor development by 
negatively inhibiting tumor suppressor genes and/or genes that control cell differentiation 
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or apoptosis [Zhang B et al, 2007] . An excellent example of ―oncomir‖ is provided by miR-
21, one of the most frequently up-regulated miRNAs in cancer [Chan JA et al 2005; Iorio 
MV et al, 2005] . One possible mechanism by which miR-21 acts as an oncogene is 
suggested by the evidence demonstrating that it targets several tumor suppressor genes, 
including PTEN, thus increasing cell proliferation and inhibiting apoptosis [Gabriely G et al, 
2008; Darido C et al, 2011] . A similar behavior is described for miRNAs 15a e 16-1 that 
negatively regulate expression of BCL2, an anti-apoptotic gene frequently over-expressed in 
several human cancers, including leukemias and lymphomas [Cimmino A et al., 2005] . Thus, 
the deletion or the down-regulation of these miRNAs would be responsible for the 
increased expression of BCL2, potentially leading to evasion of apoptosis. Instead, 
miRNAs whose expression is decreased in tumor cells are considered tumor suppressors. 
Tumor suppressor miRNAs usually prevent tumor development by negatively regulating 
and inhibiting oncogenes and/or genes that control cell differentiation or apoptosis [Zhang 
B et al, 2007] . Currently, several miRNAs are considered to be tumor suppressor genes: 
miRNA let-7a is one of the founding member of this family. The human let-7 family 
comprises 12 closely related members of miRNAs encoded by a chromosome region that is 
usually deleted in human cancer, especially lung cancers, where a strong correlation 
between low levels of the miRNA and poor prognosis has been demonstrated [Calin GA et 
al, 2004; Takamizawa J et al, 2004]. Johnson et al. reported that let-7 is down-regulated in 
lung cancer and is associated with elevates RAS expression.[Johnson SM et al, 2005] .  
 
The role of miRNAs in HCC 
During the past decade, it has been well established that specific miRNAs modulate various 
cellular processes in the liver and several studies revealed that the expression of miRNAs is 
deregulated in human HCC in comparison with matched non-neoplastic tissue and that 
their aberrant expression correlates with severity and poor prognosis of HCC [Murakami Y 
et al, 2006; Gramantieri L et al, 2008; Ura S et al, 2009; Calin GA et al, 2004; Huang XH et al, 
2009] . For example, in one study, the expression of miR-199a, miR-92, miR-106a, miR-
222, miR-17-5p, miR-18 and miR-20 correlated with the degree of tumor differentiation 
[Murakami Y et al, 2006] . In addition, it was also found that the dysregulation of miRNAs 
not only is involved in tumor progression, but it is also associated with the role of risk 
factors directly involved in tumor development, as demonstrated by the discovery that 
HBV and HCV induce different sets of miRNAs during infection [Nordenstedt H et al, 2010; 
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Ura S et al, 2009] . Although changes in the expression of microRNAs between tumor 
specimens and the normal corresponding tissue have been investigated in HCC as well, the 
obtained results are often discordant and do not allow the identification of the miRNAs 
critical for development and progression of HCC. This can be due to discordance between 
the different technical platforms employed and to the intrinsic heterogeneity of the 
different tumor populations analyzed. Furthermore, among the microRNAs whose 
expression has changed, several are probably altered not as cause but as consequence of the 
tumorigenic status. Nevertheless, several microRNAs were identified as aberrantly 
expressed by more than one study, thus indicating that irrespective of the technical 
platform or set of samples used, these microRNAs were most likely involved in liver 
tumorigenesis. Consistent deregulation of miR-122, miR-199, miR-221, and miR-21 
appears to be particularly important in HCC; among these miRNAs both miR-122 and 
miR-199a are among the miRs most highly expressed in normal liver [Hou J et al, 2011] . 
miR-122 is a hepato-specific miRNA, accounting for more than 70% of the total liver 
miRNA population and it acts as a key regulator of fatty acid and cholesterol metabolism 
[Jopling C, 2012] and as a regulator of the differentiation of adult hepatocytes via repression 
of genes not specific to the liver [Xu H et al, 2010; Esau C et al, 2006; Krutzfeldt J et al, 2006]. 
The loss of its expression was observed in more than 70% of HCC and one of the 
mechanisms through which it plays an active role in tumorigenesis appears to be the 
activation of cyclin G1 [Gramantieri L et al, 2007] . Other studies, showed that miRNAs 
associated with cell cycle inhibition (miR-34a, miR-101, miR-199-a-5p and miR-223) are 
down-regulated in HCC [Aravalli RN, 2013; Li N et al, 2009; Wong QW et al, 2008] , and 
miRs involved in cell proliferation and inhibition of apoptosis (miR-17-92 polycistron, 
miR-21, miR-96, miR-221 and miR-224) are up-regulated [Connolly E et al, 2008; Fornari F et 
al, 2008; Meng F et al, 2007; Wang Y et al, 2008] . miR-221 has received much attention for 
its suggested tumor-promoting activity. It is up-regulated in 70%-80% of HCC samples and 
HCC cells overexpressing miR-221 show increased growth, proliferation, migration, and 
invasion capability [Garofalo M et al, 2009; Pineau P et al, 2010] . miR-21 has been shown to 
be overexpressed in HCC as well as in other several human malignancies, including breast, 
colon, lung, pancreas, prostate, and stomach cancer [Volinia S et al, 2006] . Overexpression 
of miR-21 in cultured human cells can determine evasion from apoptosis and increase 
tumor cell proliferation and migration [Chan GA et al, 2005; Si ML et al, 2007] . In vivo 
miR-21 inhibition suppressed cell proliferation and increased apoptosis in a cancer 
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xenograft model [Si ML et al, 2007]. Discovery of aberrantly expressed miRNAs in HCC 
has helped to reveal novel mechanisms of liver tumorigenesis . Furthermore, since the 
profiling of miRNA expression levels in HCC could be associated with bio-pathological 
and clinical features, miRNA expression can be a potential useful tool for HCC 
classification and for improving prognostic stratification, in particular in early HCC, where 
the availability of potentially curative treatments requires a more sophisticated diagnostic 
approach. An emerging area of investigation is the potential use of miRNAs as circulating 
biomarkers. Indeed, they are present at different levels in the serum or plasma of patients 
affected by a range of disease in comparison with healthy subjects. Their stability in 
formalin-fixed and paraffin-embedded samples as well as in body fluids is an important 
property that enables their detection and quantification in biological samples. Finally, 
inhibition of oncomiRs or restoration of oncosuppressive microRNAs represent a new 
potential therapeutic approach for HCC treatment.  
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ANIMAL MODELS OF HEPATOCARCINOGENESIS 
 
The Resistant Hepatocyte model (RH)  
Unfortunately, knowledge about molecular events in early stage HCC development is 
limited because of clinical difficulties in the histopathologic distinction between non 
malignant nodular lesions (low grade and high grade dysplastic nodules) from early HCC. 
Animal models facilitate the study of different stages of hepatocarcinogenesis in that 
discrete lesions at different stage of progression can be identified and analyzed, thus 
helping to detect molecular alterations already present in early preneoplastic stages. Among 
the most widely used experimental models for the characterization of the process of liver 
carcinogenesis, in our studies we applied the resistant hepatocyte model, also known as Solt 
& Farber model, which allowed us to carry out the analysis of the different sequential steps 
leading to HCC development using the rat as animal model [Solt DB et al, 1977] . The 
system consists of three components: an initiator , diethylnitrosamine (DENA); 2-
acetylaminofluorene (2-AAF), a selective inhibitor of normal hepatocyte proliferation that 
it is ineffective against hepatocyte previously initiated by DENA, and a generalized potent 
growth stimulus represented by 70% partial hepatectomy (PH). Initiated cells undergo to 
clonal expansion to give rise to early preneoplastic lesions, identified by their 
immunohistochemistry positivity for the placental form of the enzyme glutathione-S-
transferase (GST-P). In the following weeks, nodules become macroscopically visible and 
they occupy most part of liver. During the carcinogenic process, a slow but continuous 
regression of the vast majority of the preneoplastic lesions occurs through a remodeling 
process in which hepatocytes gradually lose the staining for GST-P, and reacquire a 
differentiated phenotype [Enomoto K et al, 1982] . Conversely, only a smaller fraction of 
preneoplastic nodules progresses to develop adenomas, and after 10-14 months after 
DENA, to HCCs. GST-P+ preneoplastic nodules can be further divided into Cytokeratin-
19 (KRT-19) positive or negative lesions, depending on the expression of this protein. 
KRT-19 is a protein of the cytoskeleton intermediate filaments, normally expressed in adult 
liver by the bile duct epithelial cells, but not by normal hepatocytes [Enomoto K et al, 1982]. 
Our previous studies showed that all the HCCs arising in this model are KRT-19+, 
although only a minority of preneoplastic lesions developed at early stages of the process 
are positive for this marker. Furthermore, HCCs and KRT-19+ nodules share a common 
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gene expression profile, suggesting that rat HCC derived from this sub-population of 
KRT-19+ preneoplastic lesions [Andersen JB, Loi R et al 2010] .  
The translational value of the Resistant Hepatocyte model has already been demonstrated; 
indeed comparative genomic studies on laser capture-microdissected early lesions showed 
that the HCCs generated with the RH model have a gene expression signature very similar 
to a specific human HCC subtype that expresses KRT-19 and which is characterized by the 
worst prognosis [Andersen JB, Loi R et al, 2010] . Moreover, the finding that 78% of genes 
and 57% of miRNAs deregulated in rat HCC are similarly altered in human HCC and that 
76% of these genes were already deregulated at very early stage of the process, further 
supports the translational value of this model in predicting not only the molecular changes 
relevant to human HCC, but also the stage at which this changes occur [Petrelli A et al, 
2014] . 
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THYROID HORMONE RECEPTORS (THRs) 
 
Thyroid hormones actions 
Thyroid hormones tyroxine (T4) and triiodothyronine (T3) synthesis and secretion is 
regulated by a negative-feedback system that involves the hypothalamus, pituitary, and 
thyroid gland [hypothalamic/pituitary/thyroid (HPT) axis] [Shupnik MA et al, 1989] . 
Thyroid hormones are produced by the follicular cells of the thyroid gland, through 
iodination of the tyrosine residues [Zimmermann MB, 2009; Rubio IG and Medeiros-Neto G, 
2009] . Under physiological conditions, T4 is the main hormone secreted into the 
bloodstream by the thyroid gland but the major active form is represented by T3. 
Metabolism of thyroid hormones (THs) and conversion of T4 to the more active form T3, 
is regulated in extra-thyroidal tissues through deiodination reactions catalyzed by the 
deiodinases enzyme (DIO1, DIO2, DIO3). Type I deioidinase is responsible for the 
conversion of the majority of T4 to T3 in liver and kidney through 5‘-deiodination of the 
outer ring of T4. Type II deiodinase is found in brain, pituitary, and brown adipose tissue 
and primarily converts T4 to T3 for intracellular use. 5-deiodination by type I and type III 
deioidinase, which is found primarily in placenta, brain, and skin, leads to the generation of 
rT3, the key step for thyroid hormones inactivation. rT3 and T3 can be further deiodinated 
in the liver and sulfo- and glucuronide-conjugated before excretion in the bile [Engler D and 
Burger AG, 1984; Dayan CM and Panicker V, 2009] . There is also an enterohepatic 
circulation of TH mediated by intestinal flora that deconjugates some of these compounds 
and promotes the reuptake of THs [Yen PM, 2001] . Both T3 and T4 act via THRs. 
However, the THR binding affinity of T4 is considerably lower than that for T3. The 
physiological actions of THs affect almost every organ and system. Thyroid hormones, 
particularly T3, are potent regulators of multiple physiological activities, including cellular 
metabolic rate, heart and digestive functions, muscle function, brain development, and 
bone maintenance [YH Huang et al, 2008; Pilo A et al, 1990] . The liver has been shown to 
be a major target of thyroid hormone action [Feng X et al, 2000] . We, and other authors, 
demonstrated that T3 stimulate hepatocyte proliferation and DNA synthesis in animal 
models of liver regeneration and hyperplasia by induction of Cyclin D1 expression 
[Francavilla A et al, 1994; Bockhorn M, et al 2007; Columbano A et al, 2008; Pibiri M et al, 2001]. 
Although THs may exert their effects on a number of intracellular functions, their primary 
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effect is exerted on the transcriptional regulation of target genes via interaction with the 
thyroid hormone nuclear receptors (THRs) [Yen PM, 2001] . In addition, non-genomic 
actions of thyroid hormones, not involving direct regulation of transcription by THRs, 
have been recently described [Davis PJ et al, 2010] . 
 
Thyroid hormone receptors structure and isoforms 
THRs belong to the nuclear hormone receptor superfamily (NHR-superfamily) and act as 
T3-inducible transcription factors. The NHR-superfamily includes the steroid, vitamin D 
and retinoic acid receptors as well as ―orphan‖ receptors for which there are no known 
ligands or function [Beato M et al, 1995; Lazar MA, 1999] . Mutational analyses of THRs 
and comparison with other members of the NHR-superfamily have yielded much 
information on the structural organization of THRs [Lazar MA, 1993; Yen PM and Chin 
WW, 1994] . All THRs exhibit a modular structure organized in distinct protein domains: 
an amino-terminal domain, a central DNA-binding domain (DBD), a hinge region and a 
carboxy-terminal ligand-binding domain (LBD) [Yen PM, 2001] . [Fig.1]  
The amino-terminal Domain. The amino-terminal region has variable lengths and divergent 
sequences among the THR isoforms and among different species [Koenig RJ et al., 1988] . 
This domain is involved in modulation of cell-specific and promoter-specific transcription 
[Tora L et al, 1988; Tora L et al,1989] . Moreover, the ―A/B‖ domain of THRs recruits an 
assortment of co-regulatory proteins that can participate in ligand-independent 
transcriptional regulation [Meghan D Rosen and Martin L Privalsky, 2011] .  
The DNA binding domain (DBD). The DNA binding domain (DBD) is located in the central 
portion of THR and contains two ―zinc-fingers‖. This critical region has been shown to be 
important in sequence-specific recognition of hormone response elements of DNA and it 
is also responsible for dimerization of THRs [Rastinejad F et al, 1995] .  
The hinge region. The ―hinge region‖ bridges the DNA-binding domain and the hormone 
binding domain and contains an amino acid sequence that is associated with the nuclear 
localization of THRs [Evans RM, 1988] .  
The ligand-binding domain (LBD). The LBD is necessary for TH binding and also plays critical 
roles for dimerization, transactivation, and basal repression by unliganded THRs [Yen PM, 
2001] . This domain consists of 12-helices which are arranged to create a pocket for ligand 
binding and plays a crucial role because it is essential for the switch of the receptor from a 
silencer to an activator. In the unliganded conformation, helix 12 protrudes away from the 
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core structure of the LBD and allows co-repressor binding. Hormone binding induces helix 
12 to contact to the LBD core, resulting in co-repressor release and co-activator association 
[Apriletti et al, 1998] . 
 
THRs are encoded by two genes, THRα (NR1A1) and THRβ (NR1A2) located at separate 
loci, on human chromosomal regions 17q11.2 and 3p24.3 , and in 10q31 and 15p16 rat 
chromosomal regions. 
Rat THRα1, THRβ1, THRβ2, and THRβ3 are the major functional receptors, while several 
isoforms, THRα2, THRα3, THR∆α1, THR∆α2, and THR∆β3 are dominant-negative 
antagonists [Cheng SY et al, 2010; Williams GR 2000] [Fig.1A] . THRα2 and THRα3 result 
from alternative splicing of THRα1 mRNA, whereas the truncated variants, THR∆α1 and 
THR∆α2, are transcribed from an internal promoter located within intron 7. The THRβ2 
isoform is generated by alternative promoter usage and mRNA splicing. While the 
expression of THRα is ubiquitous and variable, THRβ is developmentally regulated [Yen 
PM, 2001] . Both THRα1 and THRβ1 are expressed in almost all rat tissues. THRβ1 
mRNA is highly expressed in brain, liver and kidney, whereas THRβ2 is transcribed in a 
tissue-specific manner in the anterior pituitary, hypothalamus, developing brain, and inner 
ear. Rat THRβ3 and THR∆β3, generated by alternative splicing, are widely expressed 
[Williams GR, 2000] . The truncated variant, THR∆β3, lacks the DNA-binding domain that 
inhibits transcriptional activation mediated by T3-liganded THRs. 
The human receptors identified to date include THRα1 and THRα2, generated from the 
THRα gene via alternative splicing, as well as THRβ1 and THRβ2 from the THRβ gene 
[Shahrara S et al., 1999; Sakurai A et al., 1989; Nakai A et al., 1988; Yen PM et al, 1992] 
[Fig.2B] . Human THRα1, THRβ1, and THRβ2 are the main ligand-binding receptors. 
Both human THRα1 and THRα2 mRNA are highly expressed in brain, prostate, and 
thyroid, and to a significantly lower extent in other tissues. The relative amounts of the 
three human THR mRNAs (THRα1, THRα2, and THRβ) are roughly comparable in each 
tissue type [Wu SM et al, 2012] . A novel human carboxy-terminal spliced variant of THRβ1 
that lacks T3-binding ability and acts as a dominant negative isoform, designated THRβ4, 
has recently been cloned. THRβ4 is widely expressed in all human tissues, but it is 
particularly abundant in testis and skeletal muscle [Tagami T et al, 2010] . Interestingly, 
whereas human THRα1, THRα2, and THRβ1 are abundant in different tissues, none of 
them is highly expressed in the liver, the major TH target organ [Mitsuhashi T et al,1988] . 
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Transcriptional activities of THRs  
THRs exert their transcriptional activities as a homodimers or as a heterodimers with other 
nuclear receptors, including retinoid X receptor (RXR) and other retinoic acid receptor 
subtypes, and vitamin D receptors (VDR). TRs generally heterodimerize with RXR; this 
heterodimer exhibits the highest T3 binding affinity and remains stable during ligand 
binding [Zhang XK and Pfahl M, 1993; Kliewer SA et al, 1992] . THRs mediate their genomic 
effects on eukaryotic transcription by binding to specific DNA elements in the promoter, 
enhancer and silencer regions of target genes. These DNA elements are known as Thyroid 
Hormone Response Elements (TREs). TREs within promoter regions of T3 target genes 
generally contain a core consensus ―half-site‖ with the sequence (A/G)GGT(C/A/G)A.  
A typical TRE contains two half-site sequences in palindromic, direct-repeat, or inverted-
repeat arrangements that are recognized by THRs [Yen PM, 2001] [Fig.2]. 
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In contrast to steroid hormone receptors that are transcriptionally inactive in the absence 
of ligand, unliganded THRs bind to TREs and may modulate transcription of target genes. 
Based on the effect of the availability of the ligand on the transcriptional activity of THRs, 
these TREs can be classified as positive (pTRE) or negative (nTRE) [Fig.3]. Liganded 
receptor leads to repression of target gene transcription in the case of nTREs and to 
activation of transcription for pTREs. In contrast, the absence of hormone, hence the 
binding of unliganded receptor leads to transcriptional activation in the case of nTREs, and 
to transcriptional repression in the case of pTREs [Eckey M et al, 2003] . 
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The mechanism of transcriptional regulation by nTREs is poorly known, while pTREs 
have been thoroughly studied. The process of transcriptional regulation for pTREs can be 
described as follow [Fig.4] : in the absence of T3, THRs usually act as transcriptional 
repressors by their association with co-repressor molecules, such as NCoR (nuclear 
receptor co-repressor) or SMRT (silencing mediator of retinoic and thyroid receptor) 
[Cheng SY et al, 2010] . NCoR and SMRT proteins serve as platform for the repressor 
complexes that contain histone deacetylases and trigger tight nucleosome remodeling 
reactions [Yoon HG, 2003] . Binding of T3 induces conformational changes in THRs that 
facilitate the recruitment of multiple co-activator complexes to the promoters of target 
genes, leading to chromatin loosening and transcriptional activation. Liganded THR 
interacts with the co-activator complex including the steroid hormone receptor CoA (SRC) 
and members of the p160 family [McKenna NJ, O’Malley BW, 2002] . SRC-1 functions as a 
histone acetyltransferase to modify chromatin structures for promoting nuclear receptor 
transactivation. The transcriptional activities of THRs are regulated by SRC/p300 and 
other large complexes, namely, THR-associated proteins (TRAPs) [Fondell JD, 1996] . 
These sequential or combinatorial complexes associated with ligand-dependent THR may 
contribute to differential responses for the appropriate expression of target genes [Glass 
CK, Rosenfeld MG , 2000] . Moreover, THRs and their co-regulators are targets of various 
post-translational modifications in response to exterior stimuli that manipulate their activity 
and alter THR-mediated gene expression [Yen PM, 2001; Lazar MA, 1993] .  
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Non-genomic effects of thyroid hormones 
A few years ago, it became evident that THs could also act through a different mechanism. 
Actions of thyroid hormones that are not triggered by liganding to intranuclear THRs are 
termed ―non-genomic‖. These processes may be initiated in the cytoplasm or in the plasma 
membrane by binding of T4 and T3 to a plasma membrane protein, the integrin αvβ3 [Cheng 
SY 2010; Bergh et al, 2005] . αvβ3 contains two binding sites, denoted as S1 and S2, which 
translate the TH signal differently [Davis et al, 2011; Freindorf et al, 2012] . S1 exclusively 
binds T3 at physiological concentrations and leads to PI3K activation. S2 binds T4 , and to a 
lesser extent T3, and ultimately activates the ERK1/2 pathway [Lin HY et al, 2009] . T4 
stimulates activation of extracellular signal-regulated kinase 1/2 (ERK1/2) through 
phospholipase C (PLC) and protein kinase Cα (PKCα). T4-activated ERK1/2 also 
modulates intracellular protein trafficking of estrogen receptor α (ERα) and THRβ1 from 
the cytoplasm to the nucleus and acts locally at the plasma membrane to activate the 
sodium proton exchanger (NHE). Complex cellular events induced from the cell surface 
receptor include angiogenesis and tumor cell proliferation [Lin HY et al 2009; Wu S et al, 
2012] . T3-induced PI3K activity may be initiated by binding to membrane-bound integrin 
αvβ3 or via a mechanism that is cytoplasmic in origin [Bhargava M et al, 2009] . Binding of 
T3 to αvβ3 activates the PI3K signal pathway via Src kinase activation leading to 
translocation of THRα1 from the cytoplasm to the nucleus and increased target gene 
expression. In the cytoplasm, T3 rapidly activates the PI3K pathway and initiates the 
downstream transcription of target genes. The T3-liganded THRβ1 in the cytoplasm 
interacts with the PI3K regulatory subunit, p85a, and induces phosphorylation of Akt (also 
known as protein kinase B, PKB) . Activated Akt translocates to the nucleus and 
subsequently phosphorylates nuclear mammalian target of rapamycin (mTOR). 
Consequently, activation of mTOR triggers the expression of ZAKI-4a (also termed 
DSCR1L, Down syndrome critical region gene 1-like) and HIF-1α. Ultimately, the pathway 
may lead to alterations in numbers of pumps inserted in the membrane and increased 
activity of the sodium pump (Na,K-ATPase) in the plasma membrane. In addition, THRα1 
interacts with the p85a subunit of PI3K in a T3-dependent manner, resulting in the 
activation of Akt and endothelial nitric oxide synthase (eNOS). Moreover, binding of 
T3/T4 to the recognition site of integrin αvβ3 can activate PI3K, stimulating shuttling of 
THRβ1 from the cytoplasm to the nucleus and increasing expression of target genes such 
as hypoxia inducible factor-1α (HIF-1α) [Lin HY et al, 2009] .  
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Many studies have indicated that THRs alterations could be involved in development and 
progression of several types of human diseases, including metabolic [Rosen MD and Privalsky 
ML, 2009] , autoimmune [Tassi V et al, 1995] , neurological [Kripke DF et al, 2009] , 
cardiovascular diseases [Goumidi L et al, 2011b] and cancers . 
 
Roles of THRs in tumorigenesis 
Several studies support the involvement of THRs in tumorigenesis. The first evidence 
came from the discovery that THRα1 is the cellular counterpart of the retroviral v-erbA 
that is involved in the neoplastic transformation leading to acute erytroleukemia and 
sarcomas [Sap et al, 1986; Thormeyer and Baniahmad, 1999] . v-erbA is an aberrant chicken 
THRα1 that does not bind T3 and has lost the ability to activate gene transcription. V-erbA 
competes with THR for binding to TREs and interferes with the normal transcription 
activity of liganded-THR on several promoters [Yen PM et al, 1994; Chen HW and Privalsky 
ML, 1993] . Thus the v-erbA oncoprotein is thought to repress constitutively, through its 
dominant negative activity, a certain set of genes that prevent cellular transformation. 
Indeed, male transgenic mice overexpressing v-erbA develop hepatocellular carcinomas, 
thereby providing evidence that v-erbA oncoprotein can promote neoplasia in mammals 
through its dominant negative activity [Barlow C et al, 1994] . Evidence of aberrant 
expression or mutations of THRs in various human cancers further supports the 
involvement of thyroid hormone receptors in oncogenesis. Loss of expression of the 
THRβ gene associated to truncation/deletion of chromosome 3p was reported in several 
malignancies including lung, melanoma, breast, head and neck, renal cell, uterine cervical, 
ovarian, and testicular tumors [Leduc F et al, 1989; Sisley K et al, 1993; Chen LC et al, 1994; 
JM Gonzales-Sancho et al, 2003; Huber-Gieseke T et al, 1997; IU Ali et al, 1989] . Decreased 
expression due to silencing of the THRβ gene by promoter hypermethylation has been 
described in several human cancers including breast, lung, and thyroid carcinoma, 
supporting the possible tumor suppressive role of this receptor. [Li Z et al, 2002; Iwasaki Y 
et al, 2010; Ling Y et al, 2010; Joseph B et al, 2007; Dunwell TL et al, 2009] . Recent studies 
provide evidence that THRβ expression could also be repressed via regulatory mechanism 
mediated by microRNAs [Jazdzewski K et al, 2011] . The THRα locus undergoes frequent 
loss of heterozigosity (LOH) in sporadic breast cancer, and rearrangement of the THRα 
gene has also been reported in leukemia, breast, and stomach cancer [Futreal PA et al,1992; 
Yokota J et al,1988; Dayton AI et al,1984] . These findings collectively suggest that THRs can 
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act as tumor suppressors in human cancer. This hypothesis is also supported by 
experiments showing that transgenic mice (THRβpv/pv) harboring a PV mutation (the PV 
mutation is a C-insertion at codon 448 of the THRB gene and leads to a frame-shift of the 
carboxyl-terminal 14 amino acids of THRβ1, resulting in total loss of T3 binding and 
transcriptional activation) originally identified in a patient with thyroid hormone resistence 
(RTH), spontaneously developed thyroid cancer [Suzuki H et al, 2002] . The THRβpv 
mutation seems also to promote breast cancer development [Guigon C et al, 2011] . 
Moreover, Zhu et al. recently showed that mice devoid of functional THRs (THRα1-/- 
THRβ-/-) spontaneously develop follicular thyroid cancer and lung metastasis [Zhu XG et al, 
2010] . Conversely, other studies suggest that THRs behave as oncogenes stimulating 
proliferation in several cancer cell types, including pituitary [Barrera-Hernandez G et al, 1999] 
, glioma [Davis FB et al, 2006] , breast [Hall LC et al, 2008] , and prostate cancer [Tsui KH et 
al, 2008] . It has been demonstrated that THRα1 through cooperation with the WNT/β-
catenin signaling pathway enhances epithelial cell proliferation and promotes intestinal 
tumorigenesis [Plateroti M et al, 2006; Kress E et al, 2009] . Despite several studies focused on 
the role of THRs in several human cancer, their role in tumor development is still unclear. 
Since actions of THRs are complex and tissue type-dependent, aberrant activity of various 
isoforms might have different effects in promoting different tumor types. 
 
Thyroid hormone levels and cancer 
As mentioned above, an aberrant activity of THRs is associated with several human 
cancers. Many reports suggest that also changes in thyroid hormone levels exert a similar 
effect but results obtained to date are ambiguous. Population-based case-control studies of 
risk factors associated to development of ovarian and pancreatic cancers found that a 
history of hyperthyroidism is associated with a twofold increase of cancer risk [Ness et al, 
2000; Ko et al, 2007] . Moreover, hyperthyroidism was associated with more advanced 
clinical stage and higher risk of recurrence in prostate cancer [Lehrer et al, 2002] . Consistent 
with hypothyroidism being beneficial, clinical studies showed that hypothyroidism 
correlates with a lower risk of primary mammary carcinoma and a reduction in progression 
to invasive disease [Cristofanilli M et al, 2005] . Similarly, farmacologically induced 
hypothyroidism improves survival in glioblastoma when used together with tamoxifen 
[Hercbergs AA et al, 2003] . In contrast, however, other studies indicate that low thyroid 
hormone levels increase the risk of HCC in humans, and high T3/T4 is therapeutic. A case 
 37 
 
control study showed that women with a history of hypothyroidism had a 2.8 fold higher 
risk of HCC [Hassan et al, 2009] .  Reddy et al. demonstrated that hypothyroidism was 
significantly more prevalent in patients with HCC of unknown etiology than in HCC 
patients with alcoholic liver disease or HCV, suggesting that hypothyroidism may be a 
permissive factor for the development of HCC [Reddy et al, 2007] . 
 
THRs in HCC 
Several studies have been performed to investigate the role of THRs in HCC development 
and progression and many reports suggest THRs as tumor suppressors in HCC. The first 
evidence was represented by the demonstration that mutated THRα (v-ErbA) leads to the 
development of hypothyroidism and HCC in male mice [Barlow C et al, 1994]. Moreover, 
several experiments have shown that mutated or truncated forms of THRs are expressed at 
high frequencies in human HCCs and in human hepatoma cell lines. These mutant forms 
of THRs display loss of transcriptional activities, defects in the release and binding of 
ligand-driven co-repressors, and act as dominant-negative forms [Lin KH et al, 1999; Chan 
IH and Privalsky ML, 2006; IH Chan and ML Privalsky, 2009; Lin KH et al, 1996; Lin KH et al, 
2001]. Nevertheless, in spite of the previously described unusual high percentage of 
mutations of THRα and THRβ genes, we did not find any mutation of both genes in rat 
HCCs [Manuscript in preparation] . Our results are in agreement with two very recent studies 
based on whole genome deep-sequencing analysis, where no mutations of THRs have been 
detected in human HCCs of different etiology [Guichard C et al, 2012; Cleary SP et al, 2013; 
Joseph B et al, 2007]. Studies conducted in hepatoma cell lines and in human HCCs have 
indicated a role for TH receptors in the induction of the tumor suppressor DKK4 via 
WNT pathway and in the repression of proto-oncogenes Sp1 and PTTG1 [Chen RN et al, 
2008; Liao CH et al, 2012] . Particular attention has been given to the THRβ1 isoform, 
representing the most abundant THR in hepatic tissue. A recent study showed that 
transfection of THRβ1 into human SKHep1 cells reduced HCC xenograft tumor growth in 
nude mice, promoted mesenchimal-to-epithelial transition and attenuated tumor cell 
invasiveness [Martinez-Iglesias O et al, 2009]. On the other hand, a less recent study showed 
that expression of THRβ1 is highly correlated with increased invasiveness in human HCC 
cell lines and decreased expression of the anti-metastatic gene nm23 [Lin KH et al, 1995]. 
The role of hypothyroidism in HCC development has also been investigated. Recent 
epidemiological studies suggested a significant association between hypothyroidism and 
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incidence of HCC, independent of other HCC risk factors [Reddy A et al, 2007; Hassan MM 
et al, 2009]. Supporting the tumor suppressor role of THRs in HCC, especially THRβ1, our 
previous studies performed using a carcinogen-induced rat HCC model, demonstrated that 
treatment of animals with T3 or the THRβ1-agonist GC1, reduced the number of 
preneoplastic nodules, HCCs and lung metastasis [Ledda-Columbano, GM et al, 2000; Perra A 
et al, 2009] . Notably, mitogenic effect of T3 in hepatocytes, is accompanied by an 
antitumoral effect probably related to activation of a differentiation program in 
preneoplastic hepatocytes [László V et al, 2008; Perra A et al, 2009] . 
Overall, despite the strong evidence suggesting a key role of THRs in HCC development, it 
is still unclear if they act as oncogenes or tumor suppressor genes.
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Aim of the work 
 
Several studies have focused on studying  alterations of thyroid hormone receptors in 
HCC, but so far it remains unclear whether they act as oncogenes or tumor suppressors. 
Previous studies performed in our laboratory on the Resistant Hepatocyte model of rat 
hepatocarcinogenesis showed that hyperthyroidism induced in rats by T3 administration 
exerts a strong antitumoral effect, inducing a rapid disappearance of preneoplastic lesions 
and the inhibition of HCC development and lung metastasis. This findings suggest that 
THRs act as tumor suppressors in rat HCC development. Therefore, the purpose of the 
present study was to investigate the role of THRs, particularly the THRβ1 isoform, in the 
hepatocarcinogenesis process. Our research has been done through the use of the Resistant 
Hepatocyte model, which allows to analyze the different stages of tumor development and 
to identify molecular alterations already present in the early stages of the process. In 
addition, to assess whether data obtained in the animal model could have a translational 
value for human hepatocarcinogenesis, we extended our studies, performing in vitro 
experiments with human hepatoma cell lines and finally evaluating THRs expression levels 
in human HCC samples. 
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Materials and methods 
 
Cell lines 
To perform in vitro experiments five human hepatoma cell lines were used, namely 
HepG2, Mahlhavu, HuH7, SKHep1C3 69.2 and HA22T/VGH, kindly provided by Dr. S. 
Giordano, IRCC Institute of Candiolo (Turin, Italy). Cells were cultured as follows: 
HepG2 cells were cultured in Dulbecco‘s Modified Eagle‘s Medium (DMEM, Life 
Technologies) supplemented with 10% fetal bovine serum (FBS, Hyclone), 2mM glutamine 
(Life Technologies) and 1% Penicillin-Streptomycin (Life Technologies). Mahlavu and 
HuH7 cells were cultured in DMEM supplemented with 10% inactivated FBS, 2mM 
glutamine and 1% penicillin-streptomycin. SKHep 1C3 69.2 cells were maintained in 
Minimal Essential Medium (MEM, Life Technologies), 10% FBS, 1% sodium pyruvate 
(Life Technologies), 1% non-essential amino-acids (NEAA, Life Technologies), and 1% 
antibiotics. HA22T/VGH were cultured in RPMI with 10% inactivated FBS, 1% sodium 
pyruvate and 1% penicillin-streptomycin. Serum has been inactivated in water bath at 56°C 
for 1 hour. Cells were maintained at 37°C in a 5% CO2 humidified atmosphere. 
 
Cell transfection  
HuH7 cells in 10cm plate were transiently transfected with 300 pmol of miRNA 
precursors: pre-miR-27a, pre-miR-181a and pre-miR-204 (Pre-miR™ miRNA Precursor 
Molecule, Life Technologies, Carlsbad, USA) or microRNA Inhibitor (Anti-miRNA 
miRNA Inhibitor molecule, Life Technologies, Carlsbad, USA) using Lipofectamine 2000 
(Life Technologies, Carlsbad, USA) following manufacturer instructions.  
For silencing of THRB expression, HuH7 cells were transfected using 300 pmol of anti-
THRB siRNA (siTHRB) and Lipofectamine 2000 (Life Technologies, Carlsbad, USA). 
Control cells were transfected using a scrambled siRNA (Silencer Negative Control, Life 
Technologies, Carlsbad, USA). One day before transfection, for each condition to be 
tested, approximately 550,000 cells were seeded in 10 cm plates to have a 30-50% 
confluence at the time of transfection. Transfection was performed as follows:  
a. 300 pmol of oligomer were diluted in 1500µL Opti-MEM I Reduced Serum Medium 
without serum. 
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b. 12 µL /10 cm plate of Lipofectamine 2000 were diluted in 1500 µL Opti-MEM and the 
mix incubated 5 min at RT.  
c. After the 5-minute incubation, the diluted oligomer was combined with the diluted 
Lipofectamine 2000. After 20 min of incubation at RT, the oligomer-Lipofectamine 2000 
complex was added to each plate containing cells and Opti-MEM.  
Cells were then incubated at 37°C in a CO2 incubator and 24 hours after transfection, cells 
were seeded with the appropriate density for subsequent biochemical and biological assays. 
RNA was extracted 72 hours after transfection and used for RT- PCR experiments. 
 
T3 treatment 
3,3′,5 Triiodo-L-thyronine sodium salt (Sigma-Aldrich, St. Louis, MO, USA) has been 
dissolved in NaOH 1M and in an appropriate volume of medium to final concentrations of 
100nM and 1µM. One day after transfection, 100˙000 HuH7 cells transfected with siC 
(scramble siRNA) and THRβ siRNA were seeded in 6 cm plates and cultured in DMEM 
supplemented with 5% FBS and treated with T3 100nM or, T3 1µM T3 and vehicle as a 
negative control. 
 
Animals 
Male Fisher F-344 rats (Charles River, Milano, Italy) weighing 100-125 gr have been used 
for the study. Animals have been fed a standard diet (Ditta Mucedola, Milano, Italy) and 
maintained at 25ºC temperature and 12 hours light/dark daily cycle, with food and water ad 
libitum. Guidelines for the Care and Use of Laboratory Animals were followed during the 
investigation. All animal procedures were approved by the Ethical Commission of the 
University of Cagliari and the Italian Ministry of Health. 
 
Experimental Protocol 
Rats belonging to the experimental group were treated in accordance with the Resistant 
Hepatocyte protocol [Fig.5]. Animals were injected i.p. with a single dose of 
diethylnitrosamine (DENA) (Sigma Aldrich, St. Louis, MO, USA), dissolved in saline, at 
the dose of 150 mg/kg body weight. After a 2-week recovery period, rats were placed on a 
diet containing 0.02% 2-acetylaminofluorene (2-AAF) (Sigma Aldrich, St. Louis, MO, 
USA) for 1 week, then subjected to a standard two-thirds partial hepatectomy (PH) [Higgins 
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GM, Anderson RM, 1931] and kept for an additional week on the 2-AAF-containing diet. 
Rats were then switched to basal diet all throughout the experiment.  
Two additional groups were used as controls: one group was subjected to the promoting 
regimen (2-AAF+PH) in the absence of carcinogen, and in a second group both the 
initiating and the promoting regimens have been omitted. 
Each experimental group was divided into two subgroups; the first of them was sacrificed 
at ten weeks from DENA administration, at a time when GSTP-positive preneoplastic 
lesions are present; the second one has been sacrificed at fourteen months to evaluate the 
presence of fully developed HCCs. HCCs were selected on the basis of the criteria 
proposed in “Histologic typing of liver tumors of the rat” [Stewart HLW, 1980] . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For assessment of THRs expression during liver regeneration, rats were subjected to a 
standard 2/3 PH according to the method described by Higgins and Anderson [Higgins 
GM, Anderson RM, 1931], and sacrificed after 24, 48 hours and one week after PH. Livers 
collected at the time of the surgery were used as controls .  
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Treatment with 5'-bromo-deoxyuridine (BrdU) 
In order to assess the proliferative activity of hepatocytes, rats subjected to the analysis of 
KRT 19- and KRT-19+ preneoplastic lesions and animals subjected to PH were treated 
with 5-bromo-2'-deoxyuridine(BrdU) (Sigma Chemical Co., St Louis, MO, USA) . 
For assessment of proliferative activity in preneoplastic lesions, BrdU was dissolved in 
drinking water (1 mg/mL) and given ad libitum for 7 days before sacrifice. For assessment 
of hepatocyte proliferation during liver regeneration associated to PH, BrdU was 
administered intra-peritoneally (i.p.) 2 hours prior to sacrifice at a dose of 50 mg/100g 
body weight.   
 
Histology and immunohistochemistry 
Tissue preparation 
Immediately after sacrifice, livers were cut into several pieces and subjected to different 
analyses. For immunohistochemistry analysis, liver sections were fixed in 10% formalin, 
embedded in paraffin and stored at RT. Other sections were frozen in cold isopentane or 
quickly frozen by immersion in liquid nitrogen and stored at -80ºC.  
 
Hematoxylin and Eosin staining 
4 μm paraffin-embedded liver sections were deparaffinized in xylene and then hydrated in a 
decreasing series of alcohol. Sections were then stained with Carazzi Hematoxylin for 15 
min and in 1% acidified alcoholic eosin for 30 seconds, then dehydrated in ascending series 
of alcohol.  
 
GST-P and KRT-19 immunohistochemistry 
6 μm isopentane-frozen liver sections were fixed in acetone at -20°C for 20 minutes. 
Endogenous peroxidases were blocked with Peroxidase Block Reagent (DAKO, Milano, 
Italy) for 10 minutes. Blocking of aspecific sites was performed in normal goat serum 1:10 
in PBS buffer for 1 hour at RT. Anti-GSTP antibody (rabbit polyclonal antibody MBL, 
Germany) was applied overnight at 4 °C at 1:1000 dilution. Sections were then incubated 
with anti-rabbit HRP secondary antibody at 1:200 dilution for 1 hour at RT. Sections were 
then stained by a brief incubation with 3-3‘ diaminobenzidine tetrahydrochloride hydrate 
(DAB) (Dako Envision, Denmark). KRT-19 protein was detected by applying anti-KRT19 
primary antibody (mouse monoclonal antibody Novocastra, Leica Biosystems, Milano) 
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diluted 1:50 for 2 hours at RT and by incubating sections with anti-mouse HRP secondary 
antibody 1:200 in PBS at RT for 1 hour. Staining was revealed by a solution containing the 
chromogenic DAB. Counter staining was performed with Harris Hematoxylin Solution 
(Sigma-Aldrich, St. Louis, MO, USA). Finally, sections were dehydrated in ascending series 
of alcohol and mounted with coverslip. 
 
BrdU staining 
Four-micrometer-thick sections were deparaffinized, treated with 2 N HCl for 1h, then 
immersed in 0.1% Trypsin Type II-S from Porcine Pancreas (Sigma-Aldrich, St. Louis, 
MO, USA) for 30 minutes at 37°C, and incubated sequentially with 1:10 Normal Goat 
Serum (Dako Denmark A/S, Glostrup, Denmark) for 30 minutes, 1:50 Mouse Monoclonal 
Anti-BrdU Antibody (Becton Dickinson, San Jose, CA, USA) for 1,5 hours and with Dako 
EnVision+ System Labeled Polymer-HRP Anti-Mouse (DakoCytomation, Carpinteria, CA, 
USA) for 30 minutes. The sites of peroxidase binding were detected by incubation with 
DAB. Counter staining was performed with Harris Hematoxylin Solution (Sigma-Aldrich, 
St. Louis, MO, USA). A segment of duodenum, an organ with a high rate of cell 
proliferation, was included from each animal to confirm delivery of BrdU. Labelling index 
was expressed as number of BrdU-positive hepatocyte nuclei per 100 nuclei. At least 2500 
hepatocyte nuclei for each liver were scored.  
 
Laser Capture Microdissection 
Pre-neoplastic lesions of animals sacrificed ten weeks after initiation were identified by 
immunohistochemical staining for GST-P and KRT-19 proteins. Fourteen-µm-thick serial 
frozen sections were attached to 2-µm PEN-membrane slides (Leica, Bannockburn, IL). 
Immediately before performing dissection, each section was rapidly stained with a 3½ 
minute H&E procedure. This step was performed in order to identify the localization of 
the lesions of our interest, which were previously identified, as mentioned above, on serial 
sections subjected to GST-P and KRT-19 IHC. Micro-dissection was performed using a 
Leica laser microdissection apparatus (LMD6000). Handling time per slide did not 
exceeded 15 minutes to avoid RNA degradation.  
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RNA extraction 
RNA extraction from preneoplastic lesions 
Total RNA was extracted from preneoplastic lesions and from respective control livers 
with mirVana miRNA Isolation kit (mirVana, Ambion, Life Technologies, Monza) 
according to manufacturer‘s instructions. Briefly, dissected lesions were dissolved in 300 μL 
of Lysis Buffer (LB) and 30 µL of miRNA Homogenate Additive. After a 10 minutes 
incubation on ice, 300 µL of acid-phenol:chloroform: isoamyl alcohol (125:24:1) were 
added to the samples. Samples were then centrifuged for 5 minutes at maximum speed to 
separate the aqueous and organic phases. After recovery of the aqueous phase, 1.25 
volumes of 100% ethanol were added and the mixture was transferred to a Filter Cartridge. 
Samples were centrifuged and after three washing steps with Wash Buffers, RNA was 
eluted in 100 µL of DEPC pre-heated (95°C) water. 
 
RNA purification from rat HCCs and control livers  
Total RNA from advanced HCCs (14 months after DENA) and control livers was isolated 
using Trizol® Reagent (Invitrogen, Carlsbad, CA, USA). 1 mL of Trizol was added to 80-
100mg of hepatic tissue and samples were homogenized with a power homogenizer. After 
a centrifugation step of 10 min at 12000 x g at 4 °C, samples were incubated 5 min at RT to 
permit the complete dissociation of nucleoprotein complexes. 0.2 mL chloroform for each 
mL of Trizol used were added and samples were centrifuged 15 min at 12000 x g. After 
centrifugation the mixture separates into a lower red phenol-chloroform phase containing 
proteins, a white interphase containing DNA, and a colorless upper aqueous phase 
containing RNA. RNA was then precipitated by addition of 500 µL isopropanol (Fisher 
Scientific, Thermo Fisher Scientific, France) and subsequently with 1 mL of 100% ethanol. 
Finally, the pellet RNA was dissolved in RNase-free water (Gibco, Life Technologies, 
Milan). In order to completely eliminate proteoglycans and polysaccharides (glycogen), the 
eluted RNA was subjected to a further purification process conducted using 3M sodium 
acetate at pH 5.2. After a second precipitation in 75% ethanol, the RNA pellet was air dried 
and then resuspended in RNase-free water. 
 
RNA purification from human hepatoma cell lines 
Total RNA of human hepatoma cell lines was extracted with miRNeasy Mini Kit 
(QIAGEN, Valencia, CA). Cells were lysed in 600 µL QIAzol Lysis Reagent and incubated 
 46 
 
5 minutes at RT (15-25 °C) to promote the dissociation of the nucleoprotein complexes. 
After addition of 140 µL chloroform and after centrifugation, the mixture separated in 
three phases. To the upper aqueous phase, containing the RNA, 500 μL of 100% ethanol 
were added and the samples were then transferred to RNeasy spin columns and centrifuged 
at 8000 x g for 15 sec at RT. Before proceeding with the purification, RNA was subjected 
to digestion with DNase in order to avoid contamination by genomic DNA. After DNA 
digestion, the RNA adsorbed to the resin of the column, was washed two times using 500 
µL of washing buffer and finally eluted with 30 µL of RNease free water by centrifugation 
for 1 min at 8000 x g. 
 
Quantitative and qualitative analysis of nucleic acids 
The quantity of RNA was measured by NanoDrop ND1000 Spectrophotometer (Thermo 
Scientific, France), while RNA integrity was assessed by Agilent Bioanalyzer 2100. Only 
RNA samples with a RIN (RNA Integrity Number) equal to 7 or higher were included in 
the study.  
 
Analysis of mRNA and miRNAs expression levels 
RT-PCR (Reverse Transcription Polymerase Chain Reaction) 
To perform the analysis of mRNA and microRNA expression, the RNA has been 
retrotranscribed to cDNA using two different protocols: 
- High Capacity cDNA Reverse Transcription Kit (Applied Biosystem, Life Technologies, 
Monza, Italy) for used for the mRNA analysis. 1.5 µg of RNA were diluted in 10 µL of 
RNase free H2O to a final concentration of 150 ng/µL. For each sample 2 μL of RT buffer 
(10X), 2 μL of Random Primers (10X), 0.8 μL of dNTPs (100 mM), 1 µL of MultiScribe 
Reverse Transcriptase enzyme, 1 μL of RNase Inhibitor and water until 20 μL were added. 
Samples were then incubated at 25 °C for 10 minutes, at 37 °C for 120 minutes and at 85 
°C for 5 minutes.  Samples were then stored at -20 °C until next use. 
- TaqMan®MicroRNA Reverse Transcription Kit (Applied Biosystem, Life Technologies, 
Monza, Italy) was used for the retrotranscription of miRNAs. 10 ng of total RNA were 
diluted to reach a final concentration of 2 ng/µL. For each sample, the retro-transcription 
mixture was composed of: 4.16 μL of H2O, 1.5 μL of Reverse Transcription Buffer (10X), 
0.15 μL of dNTPs (100 mM), 0.19 μL of RNase Inhibitor and 1 μL of MultiScribe Reverse 
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Transcriptase.  For each miRNA 3 µL of  specific primer were used. Subsequently the 
samples were incubated at 16 °C for 30 min, then at 42 °C for 30 min and at 85 °C for 5 
min. Samples were then stored at -20 °C until next use. 
 
Real Time PCR 
Retro-transcribed cDNAs were used for the assessment of mRNA and micro RNA 
expression levels by Real Time PCR. 
For gene expression analysis, the amplification reaction was performed in a final volume of 
10 µL containing: 4 μL of cDNA (2.5 ng/μL), 5 μL of TaqMan Gene Expression Master 
Mix (Applied Biosystems, Life Technologies, Monza, Italy) and 1 μL of  TaqMan probe 
(Applied Biosystems, Life Technologies, California, USA). The following TaqMan probes 
were used: 
- Rn 01464144_m1 for the analysis of rat THRα1 isoform (thyroid hormone receptor 
alpha1) 
- Rn 01464143_m1 for the analysis of rat THRα2 (thyroid hormone receptor alpha2) 
- Rn 01537799_m1 for the analysis of rat THRβ1 (thyroid hormone receptor beta1) 
- Rn 00562044_m1 targeting both rat isoforms THRβ1-β2 (a probe that recognize both 
thyroid hormone receptor beta1 and beta2 isoforms) 
- Rn 00689876_m1 for the analysis of rat G6PC (Glucose-6-phosphatase) 
- Rn 01511034_m1 for the analysis of rat THRSP/SPOT14 (Thyroid hormone responsive 
spot14) 
- Rn 00572183_m1 for the analysis of rat DIO1 (Deiodinase 1) 
- Rn 00570673 for the analysis of APP (Amyloid β precursor protein) 
- Hs 00230861_m1 for the analysis of human THRβ (thyroid hormone receptor beta) 
-Hs00174944_m1for the analysis of human DIO1 (Deiodinase 1) 
- Hs00609178_m1for the analysis of human G6PC (Glucose-6-phosphatase) 
Reactions were performed in a ABI PRISM 7300HT thermocycler (Applied Biosystems) 
with the following cycling conditions: 50 °C for 2 min and 95 °C for 10 min, followed by 
40 cycles at 95 °C for 15 sec each and a final step at 60 °C for 1 min.  
 
For the analysis of microRNAs expression, the RT product was diluted in 52 μL of H2O. 
4.5 µL of the diluted cDNA was amplified with 14.5 μL of TaqMan Universal Master Mix 
II no UNG (Applied Biosystems, Life Technologies, Monza, Italy) and 1 μL of a specific 
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TaqMan microRNA Assays (Applied Biosystems, Life Technologies, California, USA). The 
TaqMan miRNA assays used are: 
- 000397 for the analysis of miR-21,  
- 000408 for the analysis of miR-27a, 
- 000468 for the analysis of miR-146a,  
- 000480 for the analysis of miR-181a,  
- 000524 for the analysis of miR-221,  
- 000508 for the analysis of miR-204  
Parameters used to perform the reaction are: 10 min at 95°C followed by 40 cycles at 95 °C 
for 15 sec each and a final step at 60 °C for 1 min.  
 
For both mRNA and miRNAs expression, each sample was analyzed in triplicate. The 
housekeeping gene β-actin for gene expression and 4.5S (rat) and RNU48 (human) for 
miRNAs expression were used for normalization. Expression levels were evaluated with 
the 2-ΔΔCt method and represented as relative expression compared to a calibrator control. 
 
Protein isolation 
Rat liver samples were homogenized in RIPA Buffer (10 mM Tris-Cl pH 8.0, 1 mM 
EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl ) 
containing protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA), 
incubated for 2 h at 4 °C with shaking and centrifuged at 12000 rpm for 20 min at 4 °C. 
The supernatant was collected and stored at -80 °C. 
Protein concentration of whole-cell lysates was evaluated with the BCA Protein Assay kit 
(Pierce Biotechnology, Rockford, USA) and equal amounts of total proteins were used to 
perform Western blotting experiments. 
 
Western blotting 
100μg of protein were resolved in NuPAGE Tris-Acetate Mini Gel 7% (Life Technologies, 
Carlsbad, USA) and transferred to nitrocellulose membrane. Membranes were blocked for 
1 hour at RT in 5% bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO, USA) 
diluted in TBS-T buffer (NaCl 5M, Tris-HCl 1M pH 7.4, 0.1% Tween-20), washed three 
times in TBS-T for 10 min, and incubated overnight at 4 °C with anti-TRβ1 primary 
antibody (Thyroid Hormone Receptor beta-1 Monoclonal Antibody J52,  Pierce 
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Biotechnology, Rockford, IL, USA) 1:500 in 5% BSA. After washing 3 times for 10 min in 
PBS, membranes were incubated for 1 h at RT with anti-mouse horseradish peroxidase-
conjugated IgG secondary antibody at 1:10000 dilution (sc-2005, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) and then washed 3 times for 10 min in PBS. 
Proteins were detected using Supersignal West Pico Chemiluminescent Substrate (Pierce 
Biotechnology, Rockford, IL, USA). Subsequently, membranes were stripped and 
incubated 1 hour with anti-β-actin antibody diluted 1:500 (Monoclonal Anti-Actin, Clone 
AC-40, Sigma-Aldrich, St. Louis, MO, USA), washed three times with PBS and incubated 
for 1 h at RT with HRP-conjugated anti-mouse secondary antibody at 1:1500 dilution, 
washed three times and then subjected to the final detection step. Levels of TRβ1 proteins 
were normalized to Expression of the housekeeping gene β-actin was used as loading 
control.  
 
DNA extraction and CpG methylation analysis 
Genomic DNA was extracted from HCCs isolated from livers of rats subjected to the 
Resistant Hepatocyte model and from normal control livers with QIAamp DNA Mini Kit 
(QIAGEN, Valencia, CA), according with the manufacturer‘s instructions and the amount 
of extracted DNA was measured using a NanoDrop1000 spectrophotometer. 
CpG islands in the promoters of TRα and TRβ genes were localized by gathering evidence 
collected from the UCSC Genome Browser (http://genome.ucsc.edu/) [Kent WJ et al, 
2002] and analyzed for cytosine methylation in 15 HCC samples previously subjected to 
gene expression analysis.  
Promoter CpG methylation was assessed by pyrosequencing.  
2µg of DNA were bisulfite-converted with Epitect Bisulfite kit (Qiagen). Briefly, after 
addition of Bisulfite Mix ( 85µL), DNA protect  Buffer (35µL) and water to a final volume 
of 140µL, the bisulfite reaction was performed in a thermal cycler (9700 Applied 
Biosystems) following manufacturer‘s recommendations. The converted DNA was then 
purified with Epitect spin columns using appropriate buffers in accordance with 
manufacturer‘s instructions. 50 µg of converted DNA were PCR amplified in a reaction 
mix consisting of PCR-buffer 1X, 1.5mM of MgSO4, dNTPs 0.2mM each, 1 unit of 
Platinum –Taq DNA polymerase (Invitrogen) with the following forward and reverse 
primers, respectively: 5‘-GGGATTGGGATGTTAGTTT-3‘, 5‘-
ATCACACCCCAACCCTCTT-3‘. Pyrosequencing was performed according to the 
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manufacturer‘s instructions using the following sequencing primer: 5‘-
GGGATTGGGATGTTAGTTT-3‘. 10 consecutive CpGs were assessed for methylation. 
 
Patients 
HCC and cirrothic tissues were obtained from 52 consecutive patients (males and  females, 
median age ± SD: 67.2 ± 7.9, range 49-82 years) undergoing liver resection for HCC. 
Twelve normal liver tissues were obtained at surgery for large benign liver masses (5 
haemangiomas, 6 FNH (Focal nodular hyperplasia) and one traumatic liver lesion). All 
tissues were obtained by Policlinico S.Orsola-Malpighi, Bologna, Italy (Dr. L. Gramantieri). 
Tissues were collected at surgery after obtaining an informed consent, immediately frozen 
in liquid nitrogen and stored at -80°C until RNA extraction. Histopathological grading was 
scored according to Edmondson and Steiner criteria [Rozen S. & H.J. Skaletsky, 2000] . No 
patient received anticancer treatment prior to surgery. The characteristics of patients are 
detailed in Table 1. 
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Statistics 
Data are expressed as mean ± standard deviation (SD). Analysis of significance was done 
by t Student‘s test and by One-Way ANOVA using the GraphPad software (La Jolla, 
California). 
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Results 
 
Analysis of THRs expression in rat HCCs 
Deregulation of THRs expression represents a mechanism by which THRs play a role in 
the carcinogenic process in several human cancers. To establish whether THRs were 
abnormally expressed in rat HCCs, we analyzed the expression levels by Real-Time PCR of 
the THRα1 and THRβ1 isoforms in 31 HCCs isolated at 14 months after DENA 
treatment. As shown [Fig.6] , neoplastic lesions exhibited a significant decrease of the 
THRα1 [Fig.6A,B] and THRβ1 [Fig.6C,D] isoforms, compared to normal liver and to 
livers of age-matched rats exposed to AAF-PH in the absence of DENA. Notably, the 
THRβ1 isoform expression was reduced by 63% [Fig.6D] compared to normal liver, 
whereas the THRα1 isoform was reduced by 38% [Fig.6B] (P<0.01 for THRα1 and 
P<0.0001 for THRβ1).  
 
In agreement with mRNA levels, western blot analysis showed a decreased content of 
THRβ1 protein compared to normal liver [Fig.7]  
 
 53 
 
 
 
 
 
 
 
 
 
To confirm the loss of expression of the receptor, we assessed its transcriptional activity. 
To this aim, we evaluated the levels of expression of THRβ1-regulated target genes. 
Decreased levels of target genes positively regulated by T3 such as DIO1, G6PC and 
SPOT14 [Feng X et al, 2000] were observed in HCCs compared to normal liver. Conversely, 
amyloid-β precursor protein (APP), a gene that is negatively regulated by THRβ [O’Barr SA 
et al, 2006], was significantly up-regulated in the same tumors. [Fig.8].  
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of THRs expression in preneoplastic lesions 
The RH model allows to dissect the different steps of the carcinogenic process as it is 
possible to isolate phenotypically distinct lesions at well-defined stages, including very early 
preneoplastic lesions. This allows to decipher molecular alterations which occur during 
early stages of the tumoral process. Therefore, to determine whether THRs down-
regulation is an early event during liver carcinogenesis, we isolated preneoplastic lesions 
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developed 10 weeks after initiation and identified by their immunohistochemical positivity 
for the placental form of Glutathione-S-transferase (GST-P) [Satoh K et al, 1985] and 
analyzed THR expression levels. As shown [Fig.9] , a significant reduction of expression 
of THR isoforms was observed in these lesions compared to the liver of control rats 
(P<0.001 for THRα1; P<0.0001 for THRβ1 ). 
Notably, similar to HCC, a higher decrease of the expression of THRβ1 [Fig.9B] (more 
than 50% compared to normal liver samples) was observed when compared to that of 
THRα1 [Fig.9A] (30% reduction of expression).  
 
 
We conclude that down-regulation of THRs matches the onset of hepatic preneoplastic 
lesions, and that continued down-regulation of THRs expression is probably necessary for 
the maintenance and progression of these lesions. 
 
THRs expression levels in rat KRT-19-/KRT-19+ preneoplastic lesions 
It is well established that during the carcinogenic process, a slow but continuous regression 
of the vast majority of the pre-neoplastic lesions occurs, that is characterized by a 
progressive loss of the less-differentiated phenotype and by the return to a normal one 
(remodeling) [Enomoto K et al, 1982]. Our previous studies have shown that the vast 
majority of HCCs arising in the RH model of hepatocarcinogenesis are KRT-19 positive, 
despite the fact that they represent a minority of the preneoplastic lesions developed at 
early stages of the process [Andersen JB, Loi R et al 2010]. This suggests that the subset of 
KRT-19+ lesions has an intrinsic advantage in the progression to malignancy. Therefore, it 
is critical to understand whether down-regulation of THRs occurs in all preneoplastic 
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populations or it discriminates between KRT-19+ or KRT-19- subpopulations. To this 
aim, we microdissected both KRT-19+ and KRT-19- nodules and analyzed THRs 
expression in both preneoplastic nodule populations. The results showed a significant 
down-regulation of both THRα1 and THRβ1 only in KRT-19+ preneoplastic lesions, but 
not in their negative counterpart [Fig.10] (mean expression for THRα1 in KRT-19+ vs 
KRT-19- vs normal liver: 0.67 ± 0.04 vs 0.82 ± 0.04 vs 1.00 ± 0.03; mean expression for 
THRβ1: 0.46 ± 0.02 vs 0.85 ± 0.05 vs 1.00 ± 0.04). In agreement with results obtained 
from HCC, down-regulation of THRβ1 [Fig.10C,D] was much more pronounced than 
that of THRα1 [Fig.10A,B]. Therefore, subsequent studies are focused on THRβ1.  
 
 
To confirm down-regulation of THRβ1 in preneoplastic lesions, we determined expression 
levels of the already characterized target genes DIO1, G6PC and SPOT14. Similarly to 
what observed in HCCs, all these target genes were profoundly down-regulated in KRT-
19+ lesions when compared to control liver or to KRT-19- preneoplastic nodules [Fig.11] 
confirming that THRβ1 mRNA reduction also reflects a reduced transcriptional activity of 
this receptor.  
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Our results suggest that the downregulation of THRβ1 results in decreased expression of 
its target gene DIO1 that leads to the reduction of T4 to T3 conversion and to a negative 
loop causing local hypothyroidism. In order to verify this hypothesis we exposed human 
hepatoma cells to increasing concentrations of T3 and assessed THRβ levels of expression. 
To this aim we analyzed the levels of expression of THRβ in 5 human hepatoma cells, 
namely HepG2, HuH7, SKHep1C3, Mahlavu and HA22T/VGH. THRβ levels in these 
cells were generally low, with the exception of HepG2 and HuH7, as demonstrated by the 
cycle threshold (Ct) for each cell line examined, ranging from about 26.7 to 30.8 for 
SKHep, Mahlavu and HA22T cells (data not shown). Interestingly, an inverse relationship 
was observed between THRβ expression levels and the degree of cell differentiation 
[Fig.17F]. Indeed, more differentiated hepatoma cells (HepG2, HuH7), exhibited much 
higher levels of the receptor than less differentiated cell lines (SKHep1C3, Mahlavu and 
HA22T/VGH)[Yuzugullu H et al, 2009]. Among the human hepatoma cell lines, we selected 
for further experiments the HuH7 cells since they showed high levels of expression of 
THRβ. HuH7 cells were transfected with a siRNA targeting THRβ mRNA in order to 
down-regulate THRβ expression and with a control siRNA. This resulted in about a 70% 
decrease of THRβ expression in siRNA transfected cells compared to cells transfected with 
a control siRNA [Fig.12] . Furthermore, THRβ downregulation resulted in decreased 
expression levels of its direct target genes DIO1 and G6PC (about a 40% and 80% 
reduction compared to controls, respectively) [Fig.12] .  
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In order to address whether exposure of HuH7 cells to increasing concentrations of T3 
could result in the restoration of THRβ levels, we treated the transfected HuH7 cells with 
T3, 100nM and 1µM and assessed THRβ mRNA expression. In cells transfected with the 
siRNA that targets THRβ the expression of the receptor was slightly increased compared 
to control (relative expression for THRβ in HuH7+T3 1µM vs HuH7+T3 100nM vs HuH7 
non treated (NT): 0.43 vs 0.40 vs 0.29); while in cells transfected with irrelevant siRNA we 
observed a much higher increase of THRβ levels (fold change for THRβ in HuH7+T3 1µM 
vs HuH7+T3 100nM vs HuH7 NT: 1.42 vs 1.74 vs 1.0) [Fig.13] . 
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Therefore in HuH7 cells cultured in T3 supplemented conditions, higher levels of THRβ 
receptor were observed, suggesting that THRβ expression may be affected by the 
availability of its ligand T3.  
 
THRβ1 expression is down-regulated in proliferating normal and 
preneoplastic hepatocytes. 
Since KRT-19+ preneoplastic lesions are the precursor cell population of HCC and display 
the highest down-regulation of THRβ1 expression, we sought to determine whether the 
striking decrease of THRβ1 mRNA levels could be associated to an enhanced proliferative 
capacity of KRT-19+ preneoplastic hepatocytes. For this purpose, we determined BrdU 
incorporation as an index of proliferative activity in preneoplastic lesions. We treated 
animals with BrdU dissolved in drinking water for seven days and until two hours before 
sacrifice. Thus, we assessed nuclear BrdU incorporation in GST-P+, KRT-19- and KRT-
19+ preneoplastic nodules [Fig.14] .  
As shown [Fig.14G] KRT-19+ lesions had, indeed, a much higher proliferative activity 
than KRT-19 negative preneoplastic nodule hepatocytes The number of BrdU-positive 
nuclei/mm2 in KRT-19+ vs KRT-19- was 606.04±10.42 vs 283.23±16.82. (P<0.0001).  
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Notably, when we performed experiments on regenerating livers of animals subjected only 
to 2/3 PH and sacrificed at different timings after surgery, we demonstrated a significant 
down-regulation of THRβ1 expression during hepatic proliferation (mean expression 48h 
vs 24h after PH vs control: 0.30±0.04 vs 0.44±0.02 vs 1.0±0.09) ; THRβ1 expression 
returned to basal levels at the end of the regenerative process (mean expression 168h after 
PH vs control: 0.76±0.06 vs 1.0±0.09) [Fig.15] , further supporting the suppressive role of 
THRβ1 in both normal and preneoplastic hepatocyte proliferation. 
 
 
Analysis of CpG island methylation status of THRβ gene  
Hypermethylation of gene promoter is a well-known mechanism responsible for the 
silencing of many genes, including tumor suppressors in human cancers [Baylin SB and Jones 
PA, 2011]. Silencing of the THRβ expression by hypermethylation of the promoter region 
of the THRβ gene is a frequent event in breast, lung, colon, thyroid cancers and acute 
lymphoblastic leukemia [Li Z et al, 2002; Iwasaki Y et al, 2010; Ling Y et al, 2010; Joseph B et 
al, 2007; Dunwell TL et al, 2009]. Therefore, we wished to determine whether changes in the 
methylation status of the CpG islands of the THRβ gene could be responsible for down-
regulation of this receptor. To this aim, we performed pyrosequencing experiments on 15 
rat HCCs. Very low levels of methylation (average rate of methylation in HCC vs controls 
was 4.02%±0.14 vs 4.53±0.65) of the CpG islands of THRβ were detected in the HCCs 
analyzed, with no significant differences compared to controls (P value=0.23) [Table2] . 
Thus, results make very unlikely the possibility that down-regulation of THRs is the 
consequence of a hypermethylated status of the THRβ gene promoter.  
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Investigation of the role of microRNAs in THRβ1 down-regulation  
miRNAs have been shown to play a fundamental role in the control of gene expression 
[Calin GA et al, 2006] and recent studies have provided evidence that expression of THRβ 
can be repressed by the action of microRNAs [Jazdzewski K et al, 2011]. Therefore, we 
investigated whether upregulation of miRNAs could be the cause of THRβ downregulation 
in rat HCC. Initially, we selected six miRNAs shown to target THRs in different cell types, 
namely miR-21, miR-27a, miR-181a, miR-221, miR-146a and miR-204 [Jazdzewski K et al, 
2011; Nishi H et al,2011; Master A et al, 2010]. and we measured by Real-Time PCR the 
expression levels of these miRNAs in rat HCCs. As shown [Fig.16] miR-27a, miR146a, 
miR-181a and miR-204 (miRNA vs control: 13.93±3.71 vs 1.00±0.53; 5.65±1.08 vs 
1.00±0.17; 8.12±1.03 vs 1.00±0.36; 4.34±0.65 vs 1.00±0.18, respectively) were found to be 
up-regulated in rat HCC displaying THRβ1 down-regulation.  
To investigate if up-regulation of miRNA in rat HCC could be of translational value and to 
better understand the role of miRNAs in the control of THRβ expression, we moved to in 
vitro experiments. The expression levels of the same miRNAs were assessed in five human 
hepatoma cell lines, namely HepG2, HuH7, Skep1C3, Mahlavu, HA22T. Resulting 
expression levels of THRβ mRNA and selected miRNAs are shown in [Fig.17] . 
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Interestingly, an inverse relationship between the expression of miR-27a and miR-181a 
versus THRβ was observed in the five HCC cell lines examined (r=-0.848 for miR-27a and 
r=-0.816 for miR-181a) suggesting that this two miRNAs might negatively regulate THRβ1 
expression in HCC cells [Fig.18] .  
 
 
 
In order to investigate whether miRNAs affect THRβ1 expression in human hepatoma cell 
lines, we transfected HuH7 cells with precursors of the most up-regulated miRNAs in rat 
HCC, namely miR-27a, miR-181a and miR-204 and we verified that high expression levels 
were achieved [Fig.19] .  
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Evaluation of THRβ expression levels in HuH7 cells transfected with pre-miRs respect to 
HuH7 transfected with a control siRNA (siC) or with antagomiRs revealed a significant 
decrease of the expression of THRβ mRNA [Fig.20] . 
 
 
 
 
 
 
 
 
 
 
Analysis of TRs expression in human HCC  
Next, we sought to determine whether the results obtained in the RH model could be of 
translational value for human HCC. Therefore, THRβ1 mRNA levels were determined in a 
cohort of 52 HCC patients (the characteristic of the tissue samples are described in Table 
1). THRβ1 expression levels in HCCs were compared to THRβ1 expression in matched 
cirrhotic tissues (LC) [Fig.21] and in 12 normal liver samples [Fig.22] . Similarly to what 
observed in rats, human HCCs showed down-regulation of THRβ1 compared to matched 
cirrhotic tissues (LC) and to normal livers (mean expression in HCC vs LC vs normal liver: 
1.65 ± 1,10 vs 2,34 ± 1,19 vs 3.59 ± 1.76) (Fig.B), ANOVA p<0.0001. Overall, THRβ1 
was down-regulated in 71% of HCCs, when compared to matched non-cancerous cirrhotic 
tissues and in 77% of cases when compared to normal liver tissues. Regarding THRα1 
expression, no significant difference was found across HCCs, cirrhotic tissue and normal 
liver (data not shown).  
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Discussion 
 
The role of THR genes in tumor development and progression is ambiguous. Indeed, while 
THRs act as oncogenes in several types of human cancers [Barrera-Hernandez G et al, 1999; 
Hall LC et al, 2008; Plateroti M et al, 2006; Kress E et al, 2009] , other reports have provided 
evidence that they play a tumor suppressive role [Zhu XG et al, 2010; C Barlow et al, 1994] . 
Notably, no information is available on the stage of the tumorigenic process at which 
deregulation of THRs may occur. The present study highlights the possible tumor 
suppressive role of THRs in HCC development. The main findings stemming from our 
work indicate that down-regulation of THRs, especially THRβ1, i) is a very early event in 
the multistage process of hepatocarcinogenesis, ii) is statistically significant in KRT-19+ 
preneoplastic lesions, which are considered the precursors of HCC in the R-H model, but 
not in those undergoing regression (KRT-19-), iii) occurs in about 80% of rat HCCs and 
iv) is observed in 77% or 71% of human HCCs when compared to normal livers or to 
peritumoral tissues, respectively.  
Altogether, these results demonstrate that THR down-regulation is associated to HCC 
onset and progression, in a species- and aetiology-independent fashion, and suggest that 
they act as tumor suppressor genes. Indeed, the findings that down-regulation of THRβ1 is 
associated with a higher proliferative capacity of KRT-19+ lesions and that a significant 
decrease of THRβ1 also occurs in post-surgery liver regeneration, strongly support the 
concept that this receptor acts as a negative regulator of cell proliferation.  
The observation that inhibition of the THRβ1-dependent pathway occurs in the most 
aggressive preneoplastic lesions (KRT-19+), suggests that their ―hypothyroid status‖ may 
favour their evolution and progression to HCC. The relationship between hypothyroidism 
and cancer is unclear and it is still a matter of debate. Population-based case-control studies 
of risk factors associated to development of ovarian and pancreatic cancers found that a 
history of hyperthyroidism is associated with a twofold increase of cancer risk [Ness et al, 
2000; Ko et al, 2007] . Moreover, hyperthyroidism was associated with more advanced 
clinical stage and higher risk of recurrence in prostate cancer [Lehrer et al, 2002] . Opposite 
results were obtained in two case-control studies where women with a history of 
hypothyroidism had a 2.8-fold higher risk of HCC [Hassan et al, 2009] and hypothyroidism 
was significantly more prevalent in patients with HCC of unknown etiology [Reddy et al, 
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2007] . These studies suggest that hypothyroidism can be a permissive factor for HCC 
development.  
Searching for possible mechanisms responsible for THRβ1 down-regulation we ruled out 
hypermethylation of THRβ1 promoter in rat HCC. Moreover, we could not find any 
evidence of mutations of THRs, in spite of an unusual high percentage of mutations of 
THRα1 and THRβ1 (65% and 76%, respectively) previously reported in human HCC [Lin 
KH et al., 1996; Lin KH et al, 1999] . 
However, our results are in agreement with two very recent studies based on whole exon 
deep-sequencing analysis, where no mutations of THRs have been detected in human HCC 
of different etiology [Guichard C et al, 2012; Cleary SP et al, 2013; Joseph B et al, 2007] . On the 
other hand, in rat HCC we observed an inverse relationship between THRβ1 expression 
and three miRNAs (miR-27a, miR-181a and miR-204), known to be direct regulators of 
TRs expression in other cell types [Jazdzewski K et al, 2011; Nishi H et al, 2011; Master A et 
al, 2010] . Notably, transduction of human HCC cells with these miRNAs inhibited THRβ1 
expression, suggesting that up-regulation of these miRNAs may contribute to THRβ1 
down-regulation also in HCCs.  
The strong down-regulation of THRβ1 results in decreased expression of its 
classical target gene DIO1; in turns, DIO1 inhibition leads to the reduction of T4 to T3 
conversion and to a negative loop causing  local hypothyroidism. In this context, a recent 
report suggests that miRNAs targeting DIO1 in clear cell renal carcinoma influence 
intratumoral thyroid hormone levels [Boguslawska J, 2014]. 
Indeed, these Authors demonstrate that tumor-specific changes in intracellular T3 
concentration correlate with changes of the DIO1-targeting miR-224 [Boguslawska J, 2014] . 
Notably, miR-224 is one of the most up-regulated miRNAs in KRT-19 positive 
preneoplastic lesions and HCCs [Petrelli A et al, 2014]. Collectively, these results, together 
with our present findings, provide evidence that specific miRNAs may contribute to local 
hypothyroidism in pre- and neoplastic lesions and to loss of the oncosuppressive activity of 
THRβ1. In agreement with this hypothesis, hyperthyroidism induced by T3 administration 
is able to induce a rapid disappearance of preneoplastic lesions and to inhibit HCC 
development and lung metastasis [Ledda-Columbano GM et al, 2000; Perra A et al, 2009] , 
further supporting the concept that THRs act, indeed, as tumor suppressors in HCC 
development. 
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